Methods for Treating Neuropathic Pain
A compound acting as a serotonin 5-HT 2A antagonist and partial μ-opiate receptor agonist enhances NMDA- and AMPA-mediated signaling to treat neuropathic pain effectively, reducing side effects and addiction risks, with sustained release formulations providing prolonged relief.
Patent Information
- Application Number
- JP2021559095
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-04
- Filing Date
- 2020-04-04
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-04-04
AI Technical Summary
Current treatments for neuropathic pain, such as antidepressants and anticonvulsants, have limited efficacy and are associated with significant side effects, making them inadequate for effectively managing neuropathic pain without the risk of addiction.
Administration of a compound represented by formula I or its pharmaceutical composition, which acts as a serotonin 5-HT 2A receptor antagonist, partial μ-opiate receptor agonist, and dopamine D 1 receptor modulator, enhancing NMDA- and AMPA-mediated signaling through the mTOR pathway, to treat neuropathic pain.
The compound provides effective pain relief for neuropathic pain conditions like mononeuropathy, plexopathy, and central neuropathies with reduced side effects and minimal risk of addiction, offering controlled and sustained release formulations for prolonged therapeutic effects.
Smart Images

Figure 0007581233000001 
Figure 0007581233000002 
Figure 0007581233000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is an international application claiming priority to and the benefit of U.S. Provisional Application No. 62 / 829,417, filed April 4, 2019, the contents of which are incorporated herein by reference in their entirety.
[0002] FIELD OF THEINVENTION The present invention relates to the use of certain substituted heterocyclic-fused γ-carbolines, as described herein, in free form or in pharma- ceutical acceptable salt form and / or in substantially pure form, and pharmaceutical compositions thereof, for the treatment and / or prevention of neuropathic pain. [Background technology]
[0003] 2. Background of the Invention Substituted heterocycle-fused γ-carbolines have been shown to mediate the activity of 5-HT2 receptors, particularly 5-HT 2A These compounds are known to be agonists or antagonists of the 5-HT receptor. These compounds are disclosed in U.S. Patent Nos. 6,548,493; 7,238,690; 6,552,017; 6,713,471; 7,183,282; U.S. Patent No. Re. 39680, and U.S. Patent No. Re. 39679. 2A They are disclosed as novel compounds useful for treating disorders related to receptor modulation, such as obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, headache-related conditions, social phobia, gastrointestinal disorders such as gastrointestinal motility dysfunction, and obesity. U.S. Patent No. 8,309,722 and U.S. Patent No. 7,081,455 also disclose methods for preparing substituted heterocycle-fused γ-carbolines and the use of these γ-carbolines as serotonin agonists and antagonists useful for controlling and preventing central nervous system disorders such as addictive behaviors and sleep disorders.
[0004] Also, U.S. Patent No. 8,598,119 discloses the use of certain substituted heterocycle-fused γ-carbolines for the treatment of coexisting psychotic and depressive disorders, as well as sleep disorders, depressive disorders and / or mood disorders in patients with psychosis or Parkinson's disease. In addition to disorders related to psychosis and / or depression, this patent application discloses the use of certain substituted heterocycle-fused γ-carbolines for the treatment of coexisting psychotic and depressive disorders ... the treatment of coexisting 5-HT 2A These drugs selectively antagonize the dopamine D2 pathway, thereby reducing side effects associated with the highly occupied dopamine D2 pathway or other pathways (e.g., GABA receptors) associated with conventional sedative-hypnotics (e.g., benzodiazepines). A The present application discloses and claims the use of low doses of these compounds useful for treating sleep disorders without side effects from the endothelial cell receptor (including, but not limited to, the onset of drug dependency, hypotonia, weakness, headache, blurred vision, vertigo, nausea, vomiting, epigastric distress, diarrhea, joint pain, and chest pain). U.S. Patent No. 8,648,077 also discloses a method for preparing crystalline toluenesulfonic acid addition salts of these substituted heterocyclic fused γ-carbolines.
[0005] Also, without being bound by theory, recent evidence indicates that some of the above substituted fused heterocyclic γ-carbolines may function in part by NMDA receptor antagonism via mTOR1 signaling, similar to ketamine. Ketamine is a selective NMDA receptor antagonist. Ketamine acts by a system that is not associated with common psychogenic monoamines (serotonin, norepinephrine and dopamine), which is the main reason for its extremely rapid effect. Ketamine directly antagonizes extrasynaptic glutamatergic NMDA receptors, which also indirectly results in the activation of AMPA-type glutamate receptors. Downstream effects involve brain-derived neurotrophic factor (BDNF) and mTORC1 kinase pathways. Similar to ketamine, recent evidence suggests that compounds related to the disclosed compounds increase both NMDA- and AMPA-induced currents in rat medial prefrontal cortex pyramidal neurons by activating D1 receptors, and that this is associated with increased mTORC1 signaling. International Application PCT / US2018 / 043100 (WO 2019 / 023062, the contents of which are incorporated herein by reference in their entirety) discloses such effects for certain substituted fused heterocyclic γ-carbolines, and useful therapeutic indications associated therewith.
[0006] US Patent No. 10,245,260 discloses further novel fused intercomplex gamma carbolines. These new compounds were found to exhibit serotonin receptor inhibition, SERT inhibition and dopamine receptor modulation. However, these compounds were also found to unexpectedly exhibit significant activity at μ-opiate receptors. Analogs of these novel compounds are also disclosed, for example, in International Application Publication Nos. WO 2018 / 126140, WO 2018 / 126143 and WO 2019 / 23063, the contents of which are incorporated herein by reference in their entirety. Among the indications disclosed in these publications are generally the treatment of pain, neuropathic pain and chronic pain.
[0007] For example, the compound of formula A shown below is a potent serotonin 5-HT 2A It is a receptor antagonist and a μ-opiate receptor partial biased agonist. The compound also interacts with dopamine receptors, particularly the dopamine D1 receptor. [ka] It is also believed that the compound of formula A can enhance NMDA- and AMPA-mediated signaling through the mTOR pathway through its D1 receptor activity.Therefore, the compound of formula A is useful for treating or preventing central nervous system disorders, including opiate addiction, such as opiate use disorder.
[0008] Pain is the most common reason patients seek medical care. See THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 1965-85 (Merck Sharpe & Dohme 2018). Acute pain, usually associated with tissue damage, is caused by activation of peripheral pain receptors and their specific Aδ and C sensory nerve fibers. Chronic pain resulting from continued tissue damage is thought to be caused by chronic stimulation of these same sensory pathways. However, in the case of neuropathic pain, there is no peripheral tissue damage and the pain is caused by damage or dysfunction of the nervous system itself (either peripheral or central nervous system).
[0009] Neuropathic pain may be rooted in damage or dysfunction of the underlying peripheral nerves. These include mononeuropathies such as carpal tunnel syndrome and radiculopathy, plexopathies such as nerve compression caused by tumors or herniated discs, and polyneuropathy. The mechanism behind neuropathic pain is still not fully understood, but in some cases, it may involve an increase in sodium channel density in regenerating nerves.
[0010] Neuropathic pain may also be rooted in underlying central neuropathic pain syndromes. These are thought to involve reorganization of central somatosensory processing pathways, including deafferentation pain and sympathetic-maintained pain. Deafferentation pain results from partial or complete interruption of peripheral or central afferent nerve activity, such as in postherpetic neuralgia, pain after central nervous system injury, and phantom limb pain (see after traumatic or non-traumatic [surgical] amputation). Sympathetic-maintained pain depends on efferent sympathetic nerve activity. Complex regional pain syndrome (CRPS) is often accompanied by sympathetic-maintained pain. Mechanisms may include abnormal sympathetic-somatic nerve connections (effaceus), local inflammatory changes, and / or spinal cord changes.
[0011] Symptoms of neuropathic pain can be varied and include dyesthesias (spontaneous or elicited burning pain, often with a superimposed lancinating component), hyperesthesia, allodynia (pain from previously non-noxious stimuli), and hyperalgesia (an especially unpleasant and exaggerated pain response). Symptoms are long-lasting and, when the symptoms are linked to a primary cause (such as an acute injury), the symptoms may outlast the resolution of the primary cause.
[0012] Current treatments for neuropathic pain have met with very limited success. Although some classes of medications show some efficacy, complete or near-complete resolution is unlikely. Surprisingly, traditional painkillers such as nonopioid analgesics (e.g., nonsteroidal anti-inflammatory drugs, NSAIDs) and opioid analgesics are not commonly prescribed because they lack significant efficacy and / or pose too high a risk of addiction (in the case of opioids). Instead, the most frequently prescribed medications for neuropathic pain are antidepressants and anticonvulsants. Commonly prescribed antidepressants include amitriptyline, desipramine and duloxetine. Commonly prescribed anticonvulsants include carbamazepine, gabapentin, phenytoin, pregabalin and valproate. Each of these medications is associated with different side effects and potential abuse liability.
[0013] Thus, there is a need for agents with improved ability to treat neuropathic pain with reduced propensity for side effects. Summary of the Invention
[0014] The present disclosure relates to a method of treating neuropathic pain, comprising administering to a patient in need of such treatment a compound of formula I or a pharmaceutical composition thereof, wherein the compound of formula I is in free form or in salt form (e.g., a pharma- ceutically acceptable salt form), for example, in isolated or purified free form or in salt form (e.g., a pharma- ceutically acceptable salt form). [ka] [In the formula, R 1 , H, C 1-6 Alkyl, -C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH2-OC(R a )(R b )(R c ) or -C(R 6 )(R 7 )-OC(O)-R 8and; R 2 and R 3 are independently H, D, and C 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; L is for C 1-6 Alkylene (e.g., ethylene, propylene or butylene), C 1-6 Alkoxy (e.g., propoxy or butoxy), C 2-3 Alkoxy C 1-3 Alkylene (e.g., CH2CH2OCH2), C 1-6 Alkylamino or NC 1-6 Alkyl C 1-6 Alkylamino (e.g., propylamino or N-methylpropylamino), C 1-6 Alkylthio (e.g., -CH2CH2CH2S-), C 1-6 alkylsulfonyl (e.g., -CHCHCHS(O)-), each of which may contain one or more R 4 may be substituted with a moiety; Each R 4 is independently 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; Z is selected from aryl (e.g., phenyl) and heteroaryl (e.g., pyridyl, indazolyl, benzimidazolyl, benzisoxazolyl), where the aryl or heteroaryl is selected from one or more R 4 may be substituted with a moiety; R 8 is -C(R a )(R b )(R c ), -OC(R a )(R b )(R c ), or -N(R d )(R e ) and; R a , R band R c are each independently H or C 1-24 alkyl; R d and R e are each independently H and C 1-24 alkyl; R 6 and R 7 are each independently H, C 1-6 Alkyl, carboxy and C 1-6 alkoxycarbonyl] The present invention provides a method for
[0015] In a further aspect, the disclosure further provides the use of a disclosed compound, e.g., a compound of formula I, in the manufacture of a medicament for the treatment of neuropathic pain. The disclosure further provides a disclosed compound, e.g., a compound of formula I, for use in the treatment of neuropathic pain. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Detailed Description In a first aspect, the disclosure provides a method of treating chronic and / or neuropathic pain, comprising administering to a patient in need of such treatment a compound of formula I, or any of pharmaceutical compositions I, IA, IB, IC, or P.1-P.7 comprising a compound of formula I, wherein the compound of formula I is in free form or in salt form (e.g., a pharma- ceutically acceptable salt form), such as isolated or purified free form or in salt form (e.g., a pharma- ceutically acceptable salt form): [ka] [In the formula, R 1 , H, C 1-6 Alkyl, -C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH2-OC(R a )(R b )(R c ) or -C(R6 )(R 7 )-OC(O)-R 8 and; R 2 and R 3 are independently H, D, and C 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; L is for C 1-6 Alkylene (e.g., ethylene, propylene or butylene), C 1-6 Alkoxy (e.g., propoxy or butoxy), C 2-3 Alkoxy C 1-3 Alkylene (e.g., CH2CH2OCH2), C 1-6 Alkylamino or NC 1-6 Alkyl C 1-6 Alkylamino (e.g., propylamino or N-methylpropylamino), C 1-6 Alkylthio (e.g., -CH2CH2CH2S-), C 1-6 alkylsulfonyl (e.g., -CHCHCHS(O)-), each of which may contain one or more R 4 may be substituted with a moiety; Each R 4 is independently 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; Z is selected from aryl (e.g., phenyl) and heteroaryl (e.g., pyridyl, indazolyl, benzimidazolyl, benzisoxazolyl), where the aryl or heteroaryl is selected from one or more R 4 may be substituted with a moiety; R 8 is -C(R a )(R b )(R c ), -OC(R a )(R b )(R c ), or -N(R d )(R e) and; R a , R b and R c are each independently H or C 1-24 alkyl; R d and R e are each independently H and C 1-24 alkyl; R 6 and R 7 are each independently H, C 1-6 Alkyl, carboxy and C 1-6 alkoxycarbonyl] and; The pain is caused by a peripheral neuropathy (e.g., mononeuropathy, plexopathy, radiculopathy, or polyneuropathy) or by a central neuropathy (e.g., deafferented pain or sympathetically maintained pain, e.g., complex regional pain syndrome (CRPS)); A method (Method 1) is provided.
[0017] The present disclosure provides a further exemplary embodiment, Method 1, which includes:
[0018] 1.1 R 1 is H;
[0019] 1.2 R 1 C 1-6 Method 1, comprising a compound of formula I, wherein the compound is alkyl, e.g., methyl;
[0020] 1.3 R 1 -C(O)-OC(R a )(R b )(R c ),
[0021] 1.4 R a is H and R b and R c However, each independently, C 1-24 Alkyl, e.g., C1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.3, comprising a compound of formula I, wherein:
[0022] 1.5 R a and R b is H and R c But, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.3, comprising a compound of formula I, wherein R is alkyl;
[0023] 1.6 R a , R b and R c However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.3, comprising a compound of formula I, wherein:
[0024] 1.7 R a , R b and R cMethod 1.3, comprising a compound of Formula I, wherein each is H;
[0025] 1.8 R a and R b is H and R c But, C 10-14 is alkyl (e.g., R c But CH3(CH2) 10 or CH3(CH2) 14 ), method 1.3, comprising a compound of formula I;
[0026] 1.9 R 1 -C(O)-O-CH2-OC(R a )(R b )(R c ),
[0027] 1.10 R a is H and R b and R c However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.9, comprising a compound of formula I, wherein:
[0028] 1.11 R a and R b is H and R c C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14Alkyl, C 15 Alkyl or C 16 Method 1.9, comprising a compound of formula I, wherein R is alkyl;
[0029] 1.12 R a , R b and R c However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.9, comprising a compound of formula I, wherein:
[0030] 1.13 R a , R b and R c Method 1.9, comprising a compound of Formula I, wherein each is H;
[0031] 1.14 R 1 -C(R 6 )(R 7 )-OC(O)-R 8 and R 8 -C(R a )(R b )(R c ),
[0032] 1.15 R 1 -C(R 6 )(R 7 )-OC(O)-R 8 and R 8 -OC(R a )(R b )(R c ),
[0033] 1.16 Ra is H and R b and R c However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.14 or 1.15 comprising a compound of Formula I, wherein R is selected from alkyl;
[0034] 1.17 R a and R b is H and R c But, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.14 or 1.15 comprising a compound of Formula I, wherein R is alkyl;
[0035] 1.18 R a , R b and R c However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16Method 1.14 or 1.15 comprising a compound of Formula I, wherein R is selected from alkyl;
[0036] 1.19 R a , R b and R c Method 1.14 or 1.15 comprising a compound of Formula I, wherein each is H;
[0037] 1.20 R 6 is H and R 7 C 1-3 is alkyl (e.g., R 7 is methyl or isopropyl), R 8 C 10-14 is alkyl (e.g., R 8 CH3(CH2) 10 or CH3(CH2) 14 any of Methods 1.14-1.19, comprising a compound of Formula I;
[0038] 1.21 R 1 -C(R 6 )(R 7 )-OC(O)-R 8 and R 8 -N(R d )(R e ),
[0039] 1.22 R d is H and R e But independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.21, comprising a compound of formula I, wherein:
[0040] 1.23 R d and R e However, each independently, C 1-24 Alkyl, e.g., C 1-20 Alkyl, C 5-20 Alkyl, C 9-18 Alkyl, C 10-16 Alkyl or C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, C 15 Alkyl or C 16 Method 1.21, comprising a compound of formula I, wherein:
[0041] 1.24 R d and R e Method 1.21, comprising a compound of Formula I, wherein each is H;
[0042] 1.25 R 6 is H and R 7 Any of Methods 1.14-1.24 comprising a compound of Formula I, wherein is H;
[0043] 1.26 R 6 C 1-6 is alkyl, R 7 C 1-6 Any of Methods 1.14-1.24 comprising a compound of Formula I, wherein R is alkyl;
[0044] 1.27 R 6 is H and R 7 C 1-6 Any of Methods 1.14-1.24 comprising a compound of Formula I, wherein R is alkyl;
[0045] 1.28 R 6 is H and R 7 Any of Methods 1.14-1.24 comprising a compound of Formula I, wherein is carboxy;
[0046] 1.29 R 6 is H and R 7 C1-6 Any of Methods 1.14-1.24 comprising a compound of Formula I which is an alkoxycarbonyl, e.g., ethoxycarbonyl or methoxycarbonyl;
[0047] 1.30 R 2 and R 3 Any of Methods 1 or 1.1-1.29 comprising a compound of formula I, wherein is H;
[0048] 1.31 R 2 is H and R 3 any of methods 1 or 1.1-1.29 comprising a compound of formula I, wherein is D;
[0049] 1.32 R 2 and R 3 any of methods 1 or 1.1-1.29 comprising a compound of formula I, wherein is D;
[0050] 1.33 L has one or more R 4 optionally substituted with a moiety, C 1-6 Alkylene (e.g., ethylene, propylene or butylene), C 1-6 Alkoxy (e.g., propoxy), C 2-3 Alkoxy C 1-3 Alkylene (e.g., CH2CH2OCH2), C 1-6 alkylamino (e.g., propylamino or N-methylpropylamino), or C 1-6 Any of Methods 1 or 1.1-1.32 comprising a compound of Formula I that is alkylthio (e.g., -CH2CH2CH2S-);
[0051] 1.34 L is unsubstituted C 1-6 Method 1.33, comprising a compound of formula I which is an alkylene (e.g., ethylene, propylene, or butylene);
[0052] 1.35 L has one or more R 4 is substituted with a moiety, C 1-6Method 1.33, comprising a compound of formula I which is an alkylene (e.g., ethylene, propylene, or butylene);
[0053] 1.36 L is unsubstituted C 1-6 Method 1.33, which comprises a compound of Formula I which is alkoxy (e.g., propoxy or butoxy);
[0054] 1.37 L has one or more R 4 is substituted with a moiety, C 1-6 Method 1.33, which comprises a compound of Formula I which is alkoxy (e.g., propoxy or butoxy);
[0055] 1.38 L is unsubstituted C 2-3 Alkoxy C 1-3 Method 1.33, which comprises a compound of Formula I, which is an alkylene (e.g., CH2CH2OCH2);
[0056] 1.39 L has one or more R 4 is substituted with a moiety, C 2-3 Alkoxy C 1-3 Method 1.33, which comprises a compound of Formula I, which is an alkylene (e.g., CH2CH2OCH2);
[0057] 1.40 R 1 , R 2 and R 3 any of Method 1 or 1.1-1.39 comprising a compound of Formula I, wherein each is H;
[0058] 1.41 L of -(CH2) n -X-, where n is an integer selected from 2, 3 and 4, and X is -O-, -S-, -NH-, -N(C 1-6 Any of methods 1 or 1.1-1.40 comprising a compound of formula I selected from:
[0059] 1.42 L of -(CH2) nMethod 1.41, comprising a compound of formula I, -X-, where n is an integer selected from 2, 3 and 4, and X is -O-;
[0060] 1.43 L of -(CH2) n -X-, where n is 3 and X is -O-, -S-, -NH-, or -N(C 1-6 Method 1.41, comprising a compound of formula I selected from -N(CH3)- (e.g., -N(CH3)-);
[0061] 1.44 L of -(CH2) n Method 1.41, comprising a compound of formula I, -X-, where n is 3 and X is CH2;
[0062] 1.45 Z has one or more R 4 Any of Methods 1 or 1.1-1.44 comprising a compound of Formula I which is an aryl (e.g., phenyl) optionally substituted with a moiety;
[0063] 1.46 Z has one or more R 4 Method 1.45, comprising a compound of Formula I, which is aryl (e.g., phenyl) substituted with a moiety;
[0064] 1.47 Z is 1, 2, 3 or 4 R 4 Method 1.46, comprising a compound of Formula I, wherein the compound is phenyl substituted with a moiety;
[0065] 1.48 1, 2, 3 or 4 R 4 Method 1.46 comprising a compound of Formula I, wherein the moieties are independently selected from halo (e.g., fluoro, chloro, bromo, or iodo) and cyano;
[0066] 1.49 Z is one R selected from halo (e.g., fluoro, chloro, bromo or iodo) and cyano. 4Method 1.46, which comprises a compound of Formula I, wherein Z is phenyl substituted with a moiety (e.g., Z is 4-fluorophenyl, or 4-chlorophenyl, or 4-cyanophenyl);
[0067] 1.50 Method 1.46 comprising a compound of Formula I, wherein Z is phenyl substituted with one fluoro (e.g., 2-fluorophenyl, 3-fluorophenyl, or 4-fluorophenyl);
[0068] 1.51 Method 1.46 comprising a compound of formula I, wherein Z is 4-fluorophenyl;
[0069] 1.52 Z has one or more R 4 Any of Methods I or 1.1-1.44 comprising a compound of Formula I which is a heteroaryl, optionally substituted with a moiety (e.g., pyridyl, indazolyl, benzimidazolyl, benzisoxazolyl);
[0070] 1.53 Method 1.52 comprising a compound of formula I, wherein said heteroaryl is a monocyclic 5- or 6-membered heteroaryl (e.g., pyridyl, pyrimidyl, pyrazinyl, thiophenyl, pyrrolyl, thiophenyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl);
[0071] 1.54 Method 1.53 comprising a compound of formula I, wherein said heteroaryl is selected from pyridyl, pyrimidinyl, and pyrazinyl;
[0072] 1.55 Method 1.52 comprising a compound of Formula I, wherein said heteroaryl is a bicyclic 9- or 10-membered heteroaryl (e.g., indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, benzodioxolyl, 2-oxo-tetrahydroquinolinyl);
[0073] 1.56 Method 1.55 comprising a compound of formula I, wherein said heteroaryl is selected from indazolyl, benzisoxazolyl, quinolinyl, benzodioxolyl, and 2-oxo-tetrahydroquinolinyl;
[0074] 1.57 Method 1.55 comprising a compound of formula I, wherein said heteroaryl is selected from indazolyl, benzisoxazolyl, and quinolinyl;
[0075] 1.58 said heteroaryl has 1, 2, 3 or 4 R 4 Any of Methods 1.52-1.57 comprising a compound of Formula I, wherein the compound is substituted with a moiety;
[0076] 1.59 1, 2, 3 or 4 R 4 The moieties are independently halo (e.g., fluoro, chloro, bromo, or iodo), cyano, hydroxy, or C 1-6 Method 1.58, comprising a compound of formula I selected from alkoxy (e.g., methoxy);
[0077] 1.60 said heteroaryl has one R selected from halo (e.g., fluoro, chloro, bromo or iodo) and cyano; 4 Method 1.58 or 1.59, comprising a compound of Formula I, which is substituted with a moiety (e.g., the heteroaryl is 6-fluoro-3-indazolyl, 6-chloro-3-indazolyl, 6-fluoro-3-benzisoxazolyl, or 5-chloro-3-benzisoxazolyl);
[0078] 1.61 The compound is, each independently, in free form or in pharma- ceutically acceptable salt form: [ka] Any of methods 1 or 1.1-1.60, comprising a compound of formula I selected from the group consisting of:
[0079] 1.62 The compound is, each independently, in free form or in pharma- ceutically acceptable salt form: [ka] Any of methods 1 or 1.1-1.60, comprising a compound of formula I selected from the group consisting of:
[0080] 1.63 The compound is, each independently, in free form or in pharma- ceutically acceptable salt form: [ka] Any of methods 1 or 1.1-1.60, comprising a compound of formula I selected from the group consisting of:
[0081] 1.64 The compound, in free form or in the form of a pharma- ceutically acceptable salt, [ka] any of methods 1 or 1.1-1.61, comprising a compound of formula I,
[0082] 1.65 Any of Methods 1 or 1.1-1.64 comprising a compound of formula I in free form;
[0083] 1.66 Any of Methods 1 or 1.1-1.64 comprising a compound of Formula I in a salt form, e.g., a pharma- ceutically acceptable salt form;
[0084] 1.67 Any of Methods 1 or 1.1-1.64 comprising a compound of Formula I, wherein the compound is in an acid addition salt form, e.g., the acid is hydrochloric acid, toluenesulfonic acid, glutamic acid, tartaric acid, malic acid, or ascorbic acid;
[0085] 1.68 Any of Methods 1 or 1.1-1.67 comprising a compound of formula I in substantially pure diastereomeric form (i.e., substantially free of other diastereomers);
[0086] 1.69 Any of Method 1 or 1.1-1.67 comprising compounds of formula I in diastereomeric excess of greater than 70%, preferably greater than 80%, more preferably greater than 90%, and most preferably greater than 95%;
[0087] 1.70 Any of Methods 1 or 1.1-1.69 comprising a compound of Formula I in a solid form, e.g., a crystalline form;
[0088] 1.71 Any of Methods 1 or 1.1-1.70 comprising a compound of Formula I in isolated or purified form (e.g., at least 90% pure, or at least 95% pure, or at least 98% pure, or at least 99% pure);
[0089] 1.72 Any of Methods 1 or 1.1-1.71, wherein the compound of Formula I is administered in the form of a pharmaceutical composition comprising the compound of Formula I in admixture with a pharma- ceutically acceptable diluent or carrier;
[0090] 1.73 Method 1.72, wherein the compound of formula I is in pharma- ceutically acceptable salt form in admixture with a pharma- ceutically acceptable diluent or carrier;
[0091] 1.74 Method 1.72 or 1.73, wherein the pharmaceutical composition is a sustained release or delayed release formulation, e.g., according to pharmaceutical composition 1-A described herein;
[0092] 1.75 Method 1.72, 1.73 or 1.74, wherein the pharmaceutical composition comprises a compound of formula I in a polymer matrix, e.g., according to pharmaceutical composition 1-B described herein;
[0093] 1.76 Any of Methods 1.72-1.75, wherein the pharmaceutical composition is formulated as an osmotic controlled release oral delivery system, e.g., according to any of Pharmaceutical Compositions 1-C or P.1-P.7 described herein;
[0094] 1.77 Any of methods 1.72-1.76, wherein the pharmaceutical composition is in tablet or capsule form;
[0095] 1.78 Any of methods 1.72-1.77, wherein the pharmaceutical composition is formulated for oral, sublingual, or buccal administration;
[0096] 1.79 Any of methods 1.72-1.78, wherein the pharmaceutical composition is a fast dissolving oral tablet (e.g., a fast dissolving sublingual tablet);
[0097] 1.80 Any of methods 1.72-1.76, wherein the pharmaceutical composition is formulated for intranasal or pulmonary administration (e.g., as an aerosol, mist, or powder for inhalation);
[0098] 1.81 Any of methods 1.72-1.75, wherein the pharmaceutical composition is formulated for administration by injection, e.g., as a sterile aqueous solution;
[0099] 1.82 Method 1.81, wherein the pharmaceutical composition is formulated for intravenous, intrathecal, intramuscular, subcutaneous or intraperitoneal injection.
[0100] As used herein, the term "disclosed compound" refers to any of the compounds described in Method 1 or any of the embodiments of Methods 1.1-1.71.
[0101] In some embodiments, Method 1 comprises administration of a compound of the present disclosure in a sustained or delayed release formulation (Pharmaceutical Composition 1-A), e.g., a depot formulation. In some embodiments, a compound of Formula I or a compound described in Methods 1.1-1.71 is provided in an injectable depot formulation, preferably in free form or a pharma- ceutical acceptable salt form, in admixture with a pharma- ceutical acceptable diluent or carrier, providing sustained or delayed release of the compound.
[0102] In certain embodiments, pharmaceutical composition 1-A comprises a compound of formula I, or any of the disclosed compounds, in free base form or pharma- ceutically acceptable salt form, which may be in crystalline form, milled or crystallized into particles or crystals having a microparticulate or nanoparticulate size, e.g., a dose-dependent particle size (e.g., diameter or Dv50) of 0.5-100 microns, e.g., 5-30 microns, 10-20 microns, 20-100 microns, 20-50 microns, or 30-50 microns. Such particles or crystals can be combined with a suitable pharma- ceutically acceptable diluent or carrier, e.g., water, to form an injectable depot formulation. For example, the depot formulation can be formulated for intramuscular or subcutaneous injection with a dose of drug suitable for 4-6 weeks of treatment. In some embodiments, the particles or crystals have a surface area of 0.1-5 m 2 / g, e.g., 0.5 to 3.3 m 2 / g, or 0.8 to 1.2 m 2 / g.
[0103] In another embodiment, the present disclosure provides a pharmaceutical composition IB, which is a pharmaceutical composition I in which the compound of formula I (or the disclosed compound) is in a polymer matrix. In one embodiment, the disclosed compound is dispersed or dissolved in the polymer matrix. In a further embodiment, the polymer matrix comprises a standard polymer used in depot formulations, such as a polymer selected from polyesters of hydroxy fatty acids or their derivatives, or polymers of alkyl α-cyanoacrylates, polyalkylene oxalates, polyorthoesters, polycarbonates, polyortho-carbonates, polyamino acids, hyaluronic acid esters, and mixtures thereof. In a further embodiment, the polymer is selected from the group consisting of polylactide, poly d,l-lactide, polyglycolide, or PLGA, including any PLGA with a lactic acid unit to glycolic acid unit ratio of 50:50 to 90:10 (e.g., 50:50 to 75:25), such as PLGA 50:50 polymer, PLGA 85:15 polymer, and PLGA 90:10 polymer. In another embodiment, the polymer is selected from poly(glycolic acid), poly-D,L-lactic acid, poly-L-lactic acid, copolymers thereof, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactones, polydioxanones, poly(orthocarbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and natural polymers such as albumin, casein, and waxes, such as glycerol mono- and distearate. In a preferred embodiment, the polymer matrix comprises poly(d,l-lactide-co-glycolide).
[0104] Pharmaceutical composition IB is particularly useful for sustained or delayed release, where the compound of the present disclosure is released upon degradation of the polymer matrix. These compositions can be formulated (e.g., as a depot composition) for controlled and / or sustained release of the compound of the present disclosure for up to 180 days, for example, about 14 days to about 30 days to about 180 days. For example, the polymer matrix can degrade and release the compound of the present disclosure for about 30 days, about 60 days, or about 90 days. In another example, the polymer matrix can degrade and release the compound of the present disclosure for about 120 days or about 180 days.
[0105] In yet another embodiment, Pharmaceutical Composition I or IA or IB may be formulated for administration by injection, for example, as a sterile aqueous solution.
[0106] In another embodiment, the present disclosure provides a pharmaceutical composition (pharmaceutical composition IC) comprising a compound of formula I (or any of the disclosed compounds) in an osmotic release controlled oral delivery system (OROS) as described in U.S. Patent Application Publication Nos. 2001 / 0036472 and 2009 / 0202631, the contents of each of which are incorporated herein by reference in their entirety. Thus, in one embodiment, the present disclosure provides a pharmaceutical composition or device (pharmaceutical composition P.1) comprising: (a) a gelatin capsule containing a compound of any of formula I, in free form or in a pharmaceutical acceptable salt form, optionally mixed with a pharmaceutical acceptable diluent or carrier; (b) a multi-layer wall layered on the gelatin capsule, comprising, in order from the capsule outward, (i) a barrier layer, (ii) an expanding layer, and (iii) a semipermeable layer; and (c) and an orifice formed or formable through the wall.
[0107] In another embodiment, the present invention provides a pharmaceutical composition comprising a gelatin capsule containing a compound of formula I (or any of the disclosed compounds) in liquid, free form or pharma- ceutically acceptable salt form, optionally in admixture with a pharma- ceutically acceptable diluent or carrier, the gelatin capsule being surrounded by a composite wall comprising a barrier layer in contact with the outer surface of the gelatin capsule, an expanding layer in contact with the barrier layer, a semipermeable layer encompassing the expanding layer, and an exit orifice formed or formable in the wall (pharmaceutical composition P.2).
[0108] In yet another embodiment, the present invention provides a pharmaceutical composition comprising a gelatin capsule containing a compound of formula I (or any of the disclosed compounds) in liquid, free form or pharma- ceutically acceptable salt form, optionally mixed with a liquid, pharma- ceutically acceptable diluent or carrier, wherein the gelatin capsule is surrounded by a composite wall comprising a barrier layer in contact with the outer surface of the gelatin capsule, an expanding layer in contact with the barrier layer, a semipermeable layer encompassing the expanding layer, and an exit orifice formed or formable in the wall, wherein the barrier layer forms a seal between the expanding layer and the environment at the exit orifice (pharmaceutical composition P.3).
[0109] In yet another embodiment, the present invention provides a pharmaceutical composition comprising a gelatin capsule containing a compound of formula I (or any of the disclosed compounds) in liquid, free form or pharma- ceutically acceptable salt form, optionally mixed with a liquid, pharma- ceutically acceptable diluent or carrier, the gelatin capsule being surrounded by a barrier layer in contact with the outer surface of the gelatin capsule, an expanding layer in contact with a portion of the barrier layer, a semipermeable layer that encompasses at least the expanding layer, and an exit orifice formed or formable into a dosage form that extends from the outer surface of the gelatin capsule to the environment of use (pharmaceutical composition P.4). The expanding layer may be formed into one or more separate sections, for example, two sections located on opposite sides or ends of the gelatin capsule.
[0110] In certain embodiments, the compounds of the present disclosure in the osmotic controlled release oral delivery systems (i.e., compositions P.1-P.4) are in a liquid formulation, where the formulation can be a pure liquid active agent or a liquid active agent in a solution, suspension, emulsion or self-emulsifying composition, or the like.
[0111] Further information regarding osmotic release controlled oral delivery system compositions, including the characteristics of the gelatin capsule, barrier layer, expansion layer, semipermeable layer; and orifice, can be found in U.S. Patent Application Publication No. 2001 / 0036472, the contents of which are incorporated herein by reference in their entirety.
[0112] Other osmotic release controlled oral delivery systems for the compound of Formula I (or any of the disclosed compounds) or pharmaceutical compositions of the present disclosure can be found in U.S. Patent Application Publication No. 2009 / 0202631, the contents of which are incorporated herein by reference in their entirety. Thus, in another embodiment, the present invention provides a composition or device (pharmaceutical composition P.5) comprising: (a) two or more layers, including a first layer and a second layer, the first layer comprising a compound of Formula I or later in free form or in a pharma- ceutical acceptable salt form, optionally mixed with a pharma- ceutical acceptable diluent or carrier, and the second layer comprising a polymer; (b) an outer wall surrounding the two or more layers; and (c) an orifice in the outer wall.
[0113] Pharmaceutical composition P.5 preferably utilizes a semipermeable membrane surrounding a trilayer core; in these embodiments, the first layer, referred to as the first drug layer, contains a small amount of drug (e.g., a compound of Formula I or later) and an osmotic modifier such as a salt, the middle layer, referred to as the second drug layer, contains a large amount of drug and excipients and no salt, and the third layer, referred to as the push layer, contains an osmotic modifier and no drug (Pharmaceutical composition P.6). At least one orifice is drilled through the membrane at the first drug layer end of the capsule-shaped tablet.
[0114] Pharmaceutical composition P.5 or P.6 may include a membrane defining a compartment, the membrane surrounding at least a portion of the inner protective subcoat, at least one exit orifice formed or formable therein, and the semipermeable membrane; an expanding layer located in the compartment remote from the exit orifice, the expanding layer being in fluid communication with the semipermeable portion of the membrane; a first drug layer located adjacent to the exit orifice; and a second drug layer located in the compartment between the first drug layer and the expanding layer, the drug layers comprising the disclosed compound in free form or its pharma- ceutically acceptable salt (pharmaceutical composition P.7). Depending on the relative viscosities of the first and second drug layers, different release profiles are obtained. It is essential to identify the optimal viscosity of each layer. In the present invention, the viscosity is adjusted by the addition of salt, sodium chloride. The delivery profile from the core depends on the weight, formulation, and thickness of each drug layer.
[0115] In certain embodiments, the present invention provides pharmaceutical composition P.7, wherein the first drug layer comprises a salt and the second drug layer does not comprise a salt. Pharmaceutical compositions P.5-P.7 may optionally include a flux-promoting layer between the membrane and the drug layer.
[0116] Pharmaceutical compositions P.1-P.7 are generally referred to as osmotic release controlled oral delivery system compositions.
[0117] In a further embodiment of the first aspect, the present disclosure provides a further embodiment of Method 1, as follows:
[0118] 1.83 The pain is chronic pain, method 1 or any of methods 1.1 to 1.82;
[0119] 1.84 Method 1 or any of methods 1.1 to 1.82, wherein the pain is neuropathic pain;
[0120] 1.85 Method 1.83 or 1.84, in which the chronic pain is neuropathic pain;
[0121] 1.86 Method 1 or any of Methods 1.1-1.85, wherein the pain is caused by a mononeuropathy (e.g., a single mononeuropathy), such as a focal mononeuropathy, a compressive mononeuropathy, or a strangulation mononeuropathy (e.g., carpal tunnel syndrome);
[0122] 1.87 Method 1 or any of methods 1.1 to 1.85, wherein the pain is caused by radiculopathy, e.g. caused by a herniated disc, or caused by diabetic ischemia;
[0123] 1.88 Method 1 or any of Methods 1.1-1.85, wherein the pain is caused by a plexopathy (e.g., a plexopathy caused by nerve compression (e.g., nerve compression by a neuroma, tumor, or herniated disc));
[0124] 1.89 Method 1 or any of Methods 1.1-1.85, wherein the pain is caused by multiple mononeuropathy or polyneuritis (e.g., diabetic polyneuritis);
[0125] 1.90 Method 1 or any of Methods 1.1-1.85, wherein the pain is caused by a central neuropathic pain syndrome (e.g., deafferentation pain or complex regional pain syndrome (CRPS)) or fibromyalgia;
[0126] 1.91 Pain caused by postherpetic neuralgia (PHN) or fibromyalgia, either Method 1 or Methods 1.1-1.85;
[0127] 1.92 Method 1 or any of Methods 1.1-1.85, where the pain is caused by drug-induced neurotoxicity (e.g., due to doxorubicin, etoposide, gemcitabine, ifosfamide, interferon alpha, platinum chemotherapy agents (e.g., cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin, phenanthriplatin, picoplatin, satraplatin), or vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine, or vinpocetine), or antiretroviral nucleosides (e.g., didanosine, stavudine, zalcitabine));
[0128] 1.93 Any of methods 1.83-1.92, wherein the neuropathy is an axonal neuropathy (i.e., axonopathy);
[0129] 1.94 The patient has fibromyalgia, diabetes, human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS), or cancer, either Method 1 or Methods 1.1-1.93;
[0130] 1.95 Patients receiving concomitant treatment with antiretroviral nucleosides, platinum-based antineoplastic agents, or vinca alkaloid antineoplastic agents, or have a history of prior treatment with antiretroviral nucleosides, platinum-based antineoplastic agents, or vinca alkaloid antineoplastic agents, either Method 1 or Methods 1.1-1.93;
[0131] 1.96 Pain is associated with allodynia and / or hyperalgesia, either Method 1 or Methods 1.1-1.95;
[0132] 1.97 Method 1 or any of Methods 1.1-1.96, wherein the patient also suffers from anxiety (including generalized anxiety, social anxiety, and panic disorder), depression (e.g., treatment-refractory depression and MDD), psychosis (including psychosis associated with dementia, e.g., hallucinations in advanced Parkinson's disease, or paranoid delusions), schizophrenia, migraine, substance abuse disorder, substance use disorder, opiate use disorder, or other substance dependency, e.g., stimulant dependency and / or alcohol dependency;
[0133] 1.98 The patient has been diagnosed with a substance use or abuse disorder, e.g., opiate use disorder (OUD), using any of methods 1 or 1.1-1.97;
[0134] 1.99 The patient has a history of prior substance use or abuse with an opiate or opioid drug, such as morphine, codeine, thebaine, oripavine, morphine dipropionate, morphine dinicotinate, dihydrocodeine, buprenorphine, etorphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, alpha-methylfentanyl, alfentanil, trefantinil, briffentanil, remifentanil, octofentanil, sufentanil, carfentanil, meperidine, prozine, promedol, propoxyphene, dextropropoxyphene, methadone, diphenoxylate, dezocine, pentazocine, phenazocine, butorphanol, nalbuphine, levorphanol, levomethorphan, tramadol, tapentadol, and anileridine, or a combination thereof, in any of Methods 1 or Methods 1.1-1.98;
[0135] 1.100 Any of Methods 1 or 1.1-1.99, wherein the patient is diagnosed or has been diagnosed with opiate dependence, cocaine dependence, amphetamine dependence and / or alcohol dependence, or is suffering from withdrawal from a drug or alcohol dependence (e.g., opiate dependence, cocaine dependence or amphetamine dependence);
[0136] 1.101 The patient has previously suffered an opiate overdose, either method 1 or 1.1-1.100;
[0137] 1.102 Any of Methods 1 or 1.1-1.100, wherein the method comprises administering to the patient an effective amount of a compound of formula I;
[0138] 1.103 Method 1.98, wherein the effective amount is from 1 mg to 1000 mg, e.g., from 2.5 mg to 50 mg, or, for long acting formulations, from 25 mg to 1500 mg, e.g., from 50 mg to 500 mg, or from 250 mg to 1000 mg, or from 250 mg to 750 mg, or from 75 mg to 300 mg;
[0139] 1.104 Method 1.103, wherein the effective amount is between 1 mg and 100 mg per day, e.g., between 2.5 mg and 60 mg per day, or between 2.5 mg and 45 mg per day, or between 5 mg and 25 mg per day;
[0140] 1.105 Any of the above methods, wherein the method further comprises co-administration of a selective serotonin reuptake inhibitor (SSRI), e.g., administered simultaneously, separately, or sequentially;
[0141] 1.106 Method 1.105, wherein the SSRI is selected from citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline;
[0142] 1.107 Any of the above methods, wherein the method further comprises co-administration of a serotonin-norepinephrine reuptake inhibitor (SNRI), e.g., administered simultaneously, separately, or sequentially;
[0143] 1.108 Method 1.107, wherein the SNRI is selected from venlafaxine, sibutramine, duloxetine, atomoxetine, desvenlafaxine, milnacipran, and levomilnacipran;
[0144] 1.109 Any of the above methods, wherein the method further comprises co-administration of an antipsychotic, e.g., administered simultaneously, separately, or sequentially;
[0145] 1.110 Method 1.109, wherein the antipsychotic is selected from clomipramine, chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine, molindone, perphenazine, pimozide, prochlorperazine, promazine, thioridazine, thiothixene, trifluoperazine, brexpiperazole, cariprazine, asenapine, lurasidone, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, and paliperidone;
[0146] 1.111 Any of the above methods, wherein the method further comprises co-administration of an NMDA receptor antagonist, e.g., administered simultaneously, separately, or sequentially;
[0147] 1.112 Method 1.111, wherein the NMDA receptor antagonist is selected from the group consisting of ketamine (e.g., S-ketamine and / or R-ketamine), hydroxynorketamine, memantine, dextromethorphan, dextroallorphan, dextrorphan, amantadine and agmatine, or combinations thereof;
[0148] 1.113 Any of the above methods, wherein the method further comprises co-administration of a compound that modulates GABA activity (e.g., enhances activity and facilitates GABA transmission), e.g., administered simultaneously, separately, or sequentially;
[0149] 1.114 Method 1.113, wherein the GABA modulating compound is selected from the group consisting of one or more of doxepin, alprazolam, bromazepam, clobazam, clonazepam, clorazepate, diazepam, flunitrazepam, flurazepam, lorazepam, midazolam, nitrazepam, oxazepam, temazepam, triazolam, indiplon, zopiclone, eszopiclone, zeleplon, zolpidem, gaboxadol, vigabatrin, tiagabine, EVT201 (Evotec Pharmaceuticals), and estazolam;
[0150] 1.115 The method further comprises administering, e.g., simultaneously, separately or sequentially, 5-HT 2A Any of the above methods comprising co-administration of a receptor antagonist;
[0151] 1.116 More 5-HT 2A Method 1.115, wherein the receptor antagonist is selected from one or more of pimavanserin, ketanserin, risperidone, eplivanserin, vorinanserin (Sanofi-Aventis, France), pulvanserin, MDL100907 (Sanofi-Aventis, France), HY10275 (Eli Lilly), APD125 (Arena Pharmaceuticals, San Diego, CA) and AVE8488 (Sanofi-Aventis, France);
[0152] 1.117 Any of the above methods, wherein the method further comprises co-administration of a serotonin receptor antagonist / reuptake inhibitor (SARI), e.g., administered simultaneously, separately, or sequentially;
[0153] 1.118 Method 1.117, wherein the serotonin receptor antagonist / reuptake inhibitor (SARI) is selected from the group consisting of one or more of ritanserin, nefazodone, sarzone, and trazodone;
[0154] 1.119 Any of the above methods, wherein the method further comprises the concomitant administration of an antidepressant, e.g., administered simultaneously, separately, or sequentially;
[0155] 1.120 Method 1.119, wherein the antidepressant is selected from amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine sulfate, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine;
[0156] 1.121 Any of the above methods, wherein the method further comprises co-administration of an opiate agonist or partial opiate agonist, e.g., administered simultaneously, separately, or sequentially;
[0157] 1.122 Method 1.121, wherein the opiate agonist or partial opiate agonist is a μ agonist or partial agonist, or a κ agonist or partial agonist, e.g., a mixed agonist / antagonist (e.g., a drug with partial μ agonist activity and κ antagonist activity);
[0158] 1.123 Method 1.122, wherein the opiate agonist or partial opiate agonist is buprenorphine, and optionally the method does not include concomitant treatment with an anxiolytic, e.g., a GABA compound or a benzodiazepine;
[0159] 1.124 Any of the above methods, wherein the method further comprises co-administration of an opiate receptor antagonist or inverse agonist, e.g., administered simultaneously, separately, or sequentially;
[0160] 1.125 Method 1.124, wherein the opiate receptor antagonist or inverse agonist is a full opiate antagonist, e.g., selected from naloxone, naltrexone, nalmefene, methadone, nalorphine, levallorphan, samidorphan, nalodeine, cyprodim, or nor-binaltorphimine;
[0161] 1.126 any of Methods 1 or 1.1-1.125, where the patient has previously been treated with another pain relief medication and the patient did not respond adequately to the medication (e.g. the patient's pain was not adequately relieved) or the patient suffered side effects that prevented continued treatment;
[0162] 1.127 The patient has developed or is at risk of developing an addiction to other pain-relieving medications, Method 1.126;
[0163] 1.128 If other pain relieving medications are used, they may be non-opiate analgesics (e.g. nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, oxaprozin, meclofenamic acid, mefenamic acid, phenylbutazone, indomethacin, ketorolac, diclofenac, sulindac, etodolac, tolmetin, nabumetone, piroxicam, acetaminophen, aspirin, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib), opiate analgesics (e.g. morphine, cobalt oxide, cyclosporine ... Method 1.126 or 1.127, wherein the anesthetic agent is selected from a local anesthetic (e.g., benzocaine, lidocaine, procaine, bupivacaine, tetracaine) or other drug (e.g., a tricyclic antidepressant or an anticonvulsant, such as amitriptyline, desipramine, duloxetine, pregabalin, gabapentin, valproate, carbamazepine, phenytoin).
[0164] In another embodiment, the disclosure provides any of Methods 1.1-1.128, wherein the disclosed compound or a pharmaceutical composition comprising same is administered for controlled and / or sustained release of the compound over a period of about 14 days, about 30 days to about 180 days, preferably about 30 days, about 60 days or about 90 days. Controlled and / or sustained release is effective to avoid premature discontinuation of treatment, especially for antipsychotic treatments where noncompliance or nonadherence commonly occurs.
[0165] In some embodiments, the pain is caused by postherpetic neuralgia. Postherpetic neuralgia (PHN) is a neuropathic pain that occurs due to peripheral nerve damage caused by reactivation of the varicella zoster virus.
[0166] In some embodiments, the pain is caused by fibromyalgia, e.g., the pain is a symptom of fibromyalgia. Fibromyalgia is a complex syndrome of uncertain cause or origin. It is classified as a disorder of pain processing, particularly a disorder of processing pain signals in the central nervous system. As such, it is a central neuropathic pain syndrome and is often considered an example of "central sensitization." Fibromyalgia is characterized by chronic widespread pain, often including allodynia. In the United States, only pregabalin and duloxetine are approved for the management of fibromyalgia, and existing painkillers are generally ineffective.
[0167] Patients suffering from neurological disorders that may be treated with opioid analgesics or other drugs with high abuse risk are contraindicated for such treatment if they suffer from substance use or abuse disorders, or have a previous episode of opioid addiction, opioid withdrawal or opioid overdose, or a previous episode of substance or alcohol abuse.Therefore, there is a need for alternative non-addictive treatment methods, such as the methods described herein, especially for such patients.
[0168] Substance use disorders and substance-induced disorders are two categories of substance-related disorders defined by the 5th edition of the DSM (Diagnostic and Statistical Manual of Mental Disorders, or DSM-5). Substance use disorders are a pattern of symptoms resulting from the use of a substance that an individual continues to take despite experiencing problems as a result. Substance-induced disorders are disorders that are induced by the use of a substance. Substance-induced disorders include addiction, withdrawal, substance-induced psychiatric disorders such as substance-induced psychosis, substance-induced bipolar and related disorders, substance-induced depressive disorders, substance-induced anxiety disorders, substance-induced obsessive-compulsive and related disorders, substance-induced sleep disorders, substance-induced dysfunction, substance-induced delirium, and substance-induced neurocognitive disorders.
[0169] DSM-5 includes criteria for classifying substance use disorder as mild, moderate or severe. In some embodiments of the methods described herein, the substance use disorder is selected from mild substance use disorder, moderate substance use disorder or severe substance use disorder. In some embodiments, the substance use disorder is mild substance use disorder. In some embodiments, the substance use disorder is moderate substance use disorder. In some embodiments, the substance use disorder is severe substance use disorder.
[0170] Anxiety and depression are very common comorbid disorders in patients undergoing treatment for substance use or substance abuse. A common treatment for substance abuse disorders is the combination of buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, but both of these drugs have no significant effect on anxiety or depression, and therefore a common result is that a third drug, such as a benzodiazepine anxiolytic or an SSRI antidepressant, must also be prescribed. This makes treatment regimen and patient compliance more difficult. In contrast, the disclosed compounds provide opiate antagonism along with serotonin antagonism and dopamine modulation. This can significantly enhance the treatment of patients with substance use or abuse disorders comorbid with anxiety and / or depression.
[0171] The compounds of the present disclosure may have anxiolytic properties that reduce the need for treatment with anxiolytic drugs in patients suffering from comorbid anxiety.Thus, in some embodiments, the present disclosure provides a method according to method 1 or later, in which the patient suffers from anxiety or symptoms of anxiety or is diagnosed with anxiety as a comorbid or residual disorder, and the method does not include further administration of anxiolytic drugs, such as benzodiazepines and others described herein.
[0172] In any of the embodiments of Method 1 and subsequent embodiments in which the disclosed compound is administered with one or more second therapeutic agents, the one or more second therapeutic agents can be administered as part of a pharmaceutical composition that includes the disclosed compound. Alternatively, the one or more second therapeutic agents can be administered in separate pharmaceutical compositions (e.g., pills, tablets, capsules, and injections) that are administered simultaneously, sequentially, or separately from the administration of the disclosed compound.
[0173] In a second aspect, the disclosure provides the use of a disclosed compound, e.g., any of the compounds of Formula I, or any of the embodiments of Methods 1.1-1.71, in the manufacture of a medicament for use by Method 1 or any of Methods 1.1-1.128.
[0174] In a third aspect, the disclosure provides a disclosed compound, e.g., any of the compounds of Formula I, or any of the compounds described in any of the embodiments of Methods 1.1-1.71, for use according to Method 1 or any of Methods 1.1-1.128.
[0175] Without being bound by theory, the disclosed compounds, such as the compounds of formula A, are potent 5-HT agonists that also provide moderate D2 and SERT modulation (e.g., antagonism). 2A, D1 and μ opiate modulators (e.g., antagonists). Furthermore, it has been unexpectedly found that such compounds can function as "biased" μ opiate ligands. This means that when the compounds bind to the μ opiate receptor, they can function as partial μ agonists through G protein-coupled signaling, but as μ antagonists through β-arrestin signaling. This is in contrast to conventional opiate agonists, such as morphine and fentanyl, which tend to strongly activate both G protein signaling and β-arrestin signaling. Activation of β-arrestin signaling by such drugs is believed to mediate the gastrointestinal dysfunction and respiratory depression typically mediated by opiate drugs. Thus, as a result, the compounds of the present disclosure, such as those represented by formula I, are believed to provide pain relief with less severe gastrointestinal and respiratory side effects than existing opiate analgesics. This effect has been shown in preclinical studies of oliceridine, a biased μ agonist, and in phase II and phase III clinical trials. Oliceridine has been shown to produce bias μ agonism through G protein-coupled signaling with reduced β-arrestin signaling compared to morphine, which is related to its ability to produce analgesia with reduced respiratory side effects compared to morphine. Furthermore, these compounds are believed to be useful in the treatment of opiate overdose, since they antagonize the β-arrestin pathway, inhibiting the most severe opiate side effects while still providing pain relief. Furthermore, these compounds also have a sleep-promoting effect due to their serotonergic activity. Many people suffering from chronic pain have difficulty sleeping due to pain, so these compounds may help such patients sleep through the night through the synergistic effect of serotonergic activity and opiate receptor activity.
[0176] Thus, the compounds of the present disclosure are useful for treating or preventing neuropathic pain in patients with opiate use disorder (OUD), opiate overdose or opiate withdrawal, alone or in combination with opiate antagonists or inverse agonists (e.g., naloxone or naltrexone). The compounds of the present disclosure are expected to provide potent analgesia but without the adverse effects (e.g., GI effects and pulmonary depression) and abuse potential seen with other opioid treatments (e.g., oxycodone, methadone or buprenorphine). The unique pharmacological profile of these compounds also mitigates the risk of adverse drug-drug interactions (e.g., alcohol). Thus, these compounds are particularly suitable for long-term treatment and maintenance therapy of pain in patients who cannot administer opioid or opiate agents.
[0177] In some embodiments of the present disclosure, compounds of formula I have one or more biologically labile functional groups located within the compound, such that natural metabolic activity results in removal of the labile functional group, resulting in another compound of formula I. For example, a group R 1 C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH2-OC(R a )(R b )(R c ) or -C(R 6 )(R 7 )-OC(O)-R 8 If, under biological conditions, this substitution undergoes hydrolysis to give R 1 H, and thus the original compound is converted to R 1 Some of these prodrug compounds have little or only moderate biological activity, but 1When the compound is hydrolyzed to a compound where R is H, the compound becomes highly biologically active. Thus, depending on the compound selected, administration of the compounds of the present disclosure to a patient in need thereof may result in immediate biological and therapeutic effects, or immediate and delayed biological and therapeutic effects, or only delayed biological and therapeutic effects. Thus, such prodrug compounds may be used in combination with a prodrug having R 1 In this manner, some compounds of the present disclosure are particularly suitable for formulation as long-acting injectable (LAI) or "depot" pharmaceutical compositions. Without being bound by theory, an injected "depot" containing a compound of the present disclosure slowly releases the compound into body tissues where it is slowly metabolized to form R 1 The compound of formula I is produced, wherein is H. Such depot formulations can be further tailored by the selection of appropriate components to control the rate of elution and release of the compounds of the present disclosure. Such prodrug forms of compounds related to the compound of formula I have been previously disclosed, for example, in WO 2019 / 23063.
[0178] As used herein, unless otherwise specified, "alkyl" is a saturated or unsaturated hydrocarbon moiety, e.g., from 1 to 21 carbon atoms in length; such alkyl may be straight or branched chain (e.g., n-butyl or tert-butyl), and is preferably straight chain, unless otherwise specified. For example, "C 1-21 "Alkyl" means an alkyl having 1 to 21 carbon atoms. In one embodiment, the alkyl is selected from the group consisting of one or more hydroxyl or C 1-22It may be substituted with an alkoxy (e.g., ethoxy) group. In another embodiment, the alkyl contains 1-21 carbon atoms, is preferably straight chained, and is optionally saturated or unsaturated, e.g., in some embodiments, where R1 is an alkyl chain containing 1-21 carbon atoms, preferably 6-15 carbon atoms, 16-21 carbon atoms, e.g., together with the -C(O)- to which it is attached, e.g., when cleaved from a compound of formula I, forms the residue of a natural or unnatural saturated or unsaturated fatty acid.
[0179] The term "pharmaceutical acceptable diluents or carriers" is intended to mean diluents and carriers that are useful in pharmaceutical formulations and do not contain substances that are allergenic, pyrogenic or pathogenic, and substances known to potentially cause or promote disease. Thus, pharmaceutical acceptable diluents or carriers do not include bodily fluids, such as blood, urine, cerebrospinal fluid, saliva, and the like, and their components, such as blood cells and circulating proteins. Suitable pharma- ceutically acceptable diluents and carriers can be found in any of a number of well-known treatises on pharmaceutical formulations, such as, for example, Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remington's Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; and Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999), all of which are incorporated herein by reference in their entireties.
[0180] The terms "purified," "in purified form," or "in isolated and purified form" with respect to a compound refer to the physical state of the compound after it has been isolated from a synthetic process (e.g., from a reaction mixture) or from a natural source or a combination thereof. Thus, the terms "purified," "in purified form," or "in isolated and purified form" with respect to a compound refer to the physical state of the compound after it has been obtained from a purification process described herein or known to one of skill in the art (e.g., chromatography, recrystallization, LC-MS and LC-MS / MS techniques, etc.) with sufficient purity to be characterized by standard analytical techniques described herein or known to one of skill in the art.
[0181] Unless otherwise specified, the compounds of the present disclosure can be in free base form or in salt form, for example, in pharma- ceutically acceptable salt form, for example, as an acid addition salt.Sufficiently basic compounds of the present disclosure include acid addition salts, for example, with inorganic or organic acids, for example, with hydrochloric acid or toluenesulfonic acid.Furthermore, sufficiently acidic compounds of the present disclosure include salts of alkali metals, for example, sodium or potassium salts, or salts with organic bases that provide physiologically acceptable cations.In a particular embodiment, the salt of the compounds of the present disclosure is a toluenesulfonic acid addition salt.
[0182] The compounds of the present disclosure are intended for use as pharmaceuticals, and therefore pharma- ceutically acceptable salts are preferred. Salts that are not suitable for pharmaceutical use may be useful, for example, for the isolation or purification of the free compounds of the present disclosure, and therefore are also included within the scope of the compounds of the present disclosure.
[0183] The compounds of the present disclosure may contain one or more chiral carbon atoms. Thus, the compounds exist in individual isomeric forms, such as enantiomeric or diastereomeric forms, or as mixtures of individual forms, such as racemic / diastereomeric mixtures. Any isomers in which the asymmetric center is in the (R)-, (S)-, or (R,S)-configuration may exist. It should be understood that the present invention encompasses both optically active isomers individually and their mixtures (e.g., racemic / diastereomeric mixtures). Thus, the compounds of the present disclosure may be racemic mixtures, or may be predominantly, for example, in pure or substantially pure isomeric form, for example, in an enantiomeric / diastereomeric excess ("ee") of greater than 70%, preferably greater than 80%, more preferably greater than 90%, and most preferably greater than 95%. Purification of the isomers and separation of the isomeric mixtures can be carried out by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, simulated moving bed, and the like).
[0184] Geometric isomers, by the nature of substituents on double bonds or rings, may be cis (Z) or trans (E) forms and both isomers are encompassed within the scope of the present invention.
[0185] The compounds of the present disclosure are also intended to include stable or unstable isotopes. Stable isotopes are non-radioactive isotopes that contain one additional neutron compared to the same abundant nuclide (i.e., element). The activity of compounds containing such isotopes is retained, and such compounds are also believed to have utility for measuring the pharmacokinetics of non-isotopic analogs. For example, hydrogen atoms at certain positions of the compounds of the present disclosure can be replaced with deuterium (a non-radioactive stable isotope). Examples of known stable isotopes include deuterium ( 2 H or D), 13 C. 15 N, 18 Alternatively, unstable isotopes, which are radioactive isotopes that contain multiple additional neutrons compared to the homogeneous abundant nuclide (i.e., element), e.g., 123 I,131 I, 125 I, 11 C. 18 F may be replaced by the corresponding abundant species of I, C, and F. Another example of a useful isotope of the compounds of the present disclosure is: 11 C isotopes. These radioisotopes are useful for radioimaging and / or pharmacokinetic studies of the compounds of the present disclosure. Substitution of atoms with natural isotopic distributions with heavier isotopes may also result in desirable changes in pharmacokinetic rates when these substitutions are made at sites involved in metabolism. For example, deuterium ( 2 Incorporation of H) can slow metabolic degradation if the hydrogen position is a site of enzymatic or metabolic activity.
[0186] The compounds of the present disclosure can be administered in the form of a pharmaceutical composition, a depot formulation, for example by dispersing, dissolving, suspending or encapsulating the compounds of the present disclosure in the above-mentioned polymer matrix, and the compounds are released continuously as the polymer degrades over time. The release of the compounds of the present disclosure from the polymer matrix provides a controlled and / or delayed and / or sustained release of the compounds from, for example, the pharmaceutical depot composition to the subject to which the pharmaceutical depot is administered, for example, a warm-blooded animal, for example, a human. Thus, the pharmaceutical depot delivers the compounds of the present disclosure to the subject at a concentration effective to treat a particular disease or condition for an extended period of time, for example, 14 to 180 days, preferably about 30, about 60 or about 90 days.
[0187] Polymers useful for the polymer matrix in the compositions of the present disclosure (e.g., the depot compositions of the present disclosure) include polyesters of hydroxy fatty acids and their derivatives, or other agents, such as polylactic acid, polyglycolic acid, polycitric acid, polymalic acid, poly-β-hydroxybutyric acid, ε-caprolactone ring-opening polymers, lactic acid-glycolic acid copolymers, 2-hydroxybutyric acid-glycolic acid copolymers, polylactic acid-polyethylene glycol copolymers, or polyglycolic acid-polyethylene glycol copolymers), alkyl α-cyanoacrylates (e.g., poly(butyl 2-cyanoacrylates)), and the like. The polymers may include polymers such as poly(aminobutyric acid)s, poly(alkylene oxalates) (e.g., polytrimethylene oxalate or polytetramethylene oxalate), polyorthoesters, polycarbonates (e.g., polyethylene carbonate or polyethylene propylene carbonate), polyortho-carbonates, polyamino acids (e.g., poly-gamma-L-alanine, poly-gamma-benzyl-L-glutamic acid or poly-y-methyl-L-glutamic acid), hyaluronic acid esters, and the like, one or more of which may be used.
[0188] When the polymer is a copolymer, it can be either random, block and / or graft copolymer. When the above-mentioned α-hydroxycarboxylic acid, hydroxydicarboxylic acid and hydroxytricarboxylic acid have optical activity in the molecule, any one of D-isomer, L-isomer and / or DL-isomer can be used. In particular, α-hydroxycarboxylic acid polymer (preferably lactic acid-glycolic acid polymer), its ester, poly-α-cyanoacrylic acid ester, etc. can be used, and lactic acid-glycolic acid copolymer (also called poly(lactide-α-glycolide) or poly(lactic acid-co-glycolic acid), hereinafter called PLGA) is preferred. Thus, in one embodiment, the polymer useful for the polymer matrix is PLGA. As used herein, the term PLGA includes polymers of lactic acid (also called polylactide, poly(lactic acid) or PLA). Most preferably, the polymer is a biodegradable poly(d,l-lactide-co-glycolide) polymer.
[0189] In a preferred embodiment, the polymer matrix of the present disclosure is a biocompatible and biodegradable polymeric material. The term "biocompatible" is defined as a polymeric material that is non-toxic, non-carcinogenic, and does not induce significant inflammation in body tissues. The matrix material should be biodegradable, where the polymeric material should be broken down by internal processes into products that can be easily excreted by the body and should not accumulate in the body. The products of biodegradation should also be biocompatible with the body in that the polymeric matrix is biocompatible with the body. Specific useful examples of polymer matrix materials include poly(glycolic acid), poly-D,L-lactic acid, poly-L-lactic acid, copolymers of the above, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactones, polydioxanones, poly(orthocarbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and natural polymers such as albumin, casein, and waxes such as glycerol mono- and distearate. A preferred polymer for use in the practice of the invention is dl(polylactide-co-glycolide). The molar ratio of lactide to glycolide in such copolymers is preferably in the range of about 75:25 to 50:50.
[0190] The weight average molecular weight of useful PLGA polymers can be about 5,000 to 500,000 Daltons, preferably about 150,000 Daltons. Depending on the degradation rate to be achieved, polymers of various molecular weights can be used. For a diffusion mechanism of drug release, the polymer should remain intact until all the drug is released from the polymer matrix, and then degrade. Drugs can also be released from the polymer matrix if the polymer excipient bioerodes.
[0191] PLGA may be prepared by any conventional method or may be commercially available. For example, PLGA may be prepared from cyclic lactide, glycolide, etc. by ring-opening polymerization with a suitable catalyst (see EP 0058481 B2; Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure).
[0192] PLGA is believed to be biodegradable by the degradation of the entire solid polymer composition through the decomposition of hydrolyzable and enzymatically cleavable ester bonds under biological conditions (e.g., in the presence of water and biological enzymes that can be found in the tissues of warm-blooded animals such as humans) to form lactic acid and glycolic acid. Both lactic acid and glycolic acid are water-soluble, non-toxic products of normal metabolism that can be further decomposed to form carbon dioxide and water. In other words, PLGA is believed to be decomposed in the body of a warm-blooded animal, such as a human, in the presence of water by hydrolysis of its ester groups to produce lactic acid and glycolic acid, creating an acidic microenvironment. Lactic acid and glycolic acid are by-products of various metabolic pathways in the body of a warm-blooded animal, such as a human, under normal physiological conditions, and therefore are well tolerated and have minimal systemic toxicity.
[0193] In another embodiment, the polymer matrix may comprise a star polymer, where the structure of the polyester is star-shaped. These polyesters have a single polyol residue as the central moiety surrounded by chains of acid residues. The polyol moiety may be, for example, glucose or, for example, mannitol. These esters are known and are described in GB 2,145,422 and U.S. Pat. No. 5,538,739, the contents of each of which are incorporated herein by reference.
[0194] Star polymers can be produced using polyhydroxy compounds, such as polyols, such as glucose or mannitol, as initiators. The polyols contain at least three hydroxy groups and have a molecular weight of up to about 20,000 Daltons, and at least one, preferably at least two, for example an average of three, of the hydroxy groups of the polyol are in the form of ester groups, which contain polylactide or co-polylactide chains. Branched polyesters, such as poly(d,l-lactide-co-glycolide), have a central glucose moiety with multiple linear polylactide chains.
[0195] The depot composition of the present disclosure in the above polymer matrix (e.g., pharmaceutical composition IA or IB) may include a polymer in the form of microparticles or nanoparticles or in liquid form in which the compound of the present disclosure is dispersed or encapsulated. "Microparticle" refers to a solid particle containing the compound of the present invention in either a solution or solid form in which the compound of the present disclosure is dispersed or dissolved within a polymer that acts as the matrix of the particle. By appropriate selection of the polymer material, microparticle formulations can be made in which the resulting microparticles exhibit both diffusional and biodegradable release properties.
[0196] When the polymer is in microparticle form, the microparticle can be produced by suitable methods, for example, by solvent evaporation or solvent extraction. For example, in the solvent evaporation method, the compound of the present disclosure and the polymer can be dissolved in a volatile organic solvent (e.g., ketones such as acetone, halogenated hydrocarbons such as chloroform or methylene chloride, halogenated aromatic hydrocarbons, cyclic ethers such as dioxane, esters such as ethyl acetate, nitriles such as acetonitrile, or alcohols such as ethanol) and dispersed in an aqueous phase containing a suitable emulsion stabilizer (e.g., polyvinyl alcohol, PVA). The organic solvent is then evaporated to obtain microparticles in which the compound of the present disclosure is encapsulated. In the solvent extraction method, the compound of the present disclosure and the polymer can be dissolved in a polar solvent (e.g., acetonitrile, dichloromethane, methanol, ethyl acetate or methyl formate) and then dispersed in an aqueous phase (e.g., water / PVA solution). An emulsion is prepared to provide microparticles in which the compound of the present disclosure is encapsulated. Spray drying is another manufacturing technique for producing microparticles.
[0197] Other methods for producing the microparticles of the present disclosure are also described in both US Pat. No. 4,389,330 and US Pat. No. 4,530,840.
[0198] The microparticles of the present disclosure can be manufactured by a method that can produce microparticles in a size range that is acceptable for use in injectable compositions. One preferred manufacturing method is described in U.S. Pat. No. 4,389,330. In this method, the active agent is dissolved or dispersed in a suitable solvent. To the active agent-containing medium, a polymer matrix material is added in an amount relative to the active ingredient that provides a product with the desired active agent loading. If desired, all components of the microparticle product can be blended together in a solvent medium.
[0199] Solvents for the compounds of the present disclosure and polymer matrix materials that can be used in the practice of the present invention include organic solvents such as acetone; halogenated hydrocarbons such as chloroform, methylene chloride, etc.; aromatic hydrocarbon compounds; halogenated aromatic hydrocarbon compounds; cyclic ethers; alcohols such as benzyl alcohol; ethyl acetate, etc. In one embodiment, the solvent for use in the practice of the present invention can be a mixture of benzyl alcohol and ethyl acetate. Further information regarding the preparation of microparticles useful in the present invention can be found in U.S. Patent Application Publication No. 2008 / 0069885, the contents of which are incorporated herein by reference in their entirety.
[0200] The amount of the compound of the present disclosure incorporated into the microparticles is typically in the range of about 1% to about 90% by weight, preferably 30-50% by weight, and more preferably 35-40% by weight, where weight % refers to the portion of the compound of the present disclosure per total weight of the microparticle.
[0201] The pharmaceutical depot composition may comprise a pharma- ceutically acceptable diluent or carrier, such as a water-miscible diluent or carrier.
[0202] Details of osmotic controlled release oral delivery system compositions can be found in European Patent Application Publication No. 1539115 (U.S. Patent Application Publication No. 2009 / 0202631) and International Patent Application Publication No. WO 2000 / 35419 (U.S. Patent Application Publication No. 2001 / 0036472), the contents of each of which are incorporated herein by reference in their entirety.
[0203] By "effective amount" is meant a "therapeutically effective amount," which is an amount of a compound of the present disclosure (e.g., as contained in a pharmaceutical composition or dosage form) that, when administered to a subject suffering from a disease or disorder, is effective to cause relief, remission, or regression of the disease or disorder over the period of time contemplated for treatment.
[0204] Dosages used in the practice of the present invention will of course vary depending, for example, on the particular disease or condition being treated, the particular compound of the present disclosure being used, the mode of administration, and the desired therapy.Unless otherwise specified, the amount of a compound of the present disclosure for administration (administered as a free base or salt form) refers to or is based on the amount of the compound of the present disclosure in free base form (i.e., the calculation of the amount is based on the amount of free base).
[0205] The compounds of the present disclosure may be administered by any suitable route, including orally, parenterally (intravenously, intramuscularly or subcutaneously) or transdermally. In certain embodiments, the compounds of the present disclosure, for example in a depot formulation, are preferably administered parenterally, for example by injection, for example intramuscularly or intravenously.
[0206] In general, it has been shown that satisfactory results for the above method 1 and subsequent methods can be obtained by oral administration at a dose of about 1 mg to 100 mg once a day, preferably 2.5 mg to 50 mg, for example 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg or 50 mg once a day.
[0207] For the treatment of disorders described herein, where a depot composition is used to achieve a longer duration of action, the dosage is higher than that of a short acting composition, e.g., higher than 1-100 mg, e.g., 25 mg, 50 mg, 100 mg, 500 mg, 1000 mg, or more than 1000 mg. The duration of action of the compounds of the present disclosure can be controlled by manipulating the polymer composition, i.e., the polymer:drug ratio, and the microparticle size. When the composition of the present disclosure is a depot composition, administration by injection is preferred.
[0208] The pharmaceutically acceptable salt of the compounds of the present disclosure can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods.Generally, such salts can be prepared by reacting the free base form of these compounds with stoichiometric amount of suitable acid in water or organic solvent or the mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.Further details on the preparation of these salts, such as toluenesulfonate salts in amorphous or crystalline form, can be found in US Patent Application Publication No. 2011 / 112105.
[0209] Pharmaceutical compositions containing the compounds of the present disclosure can be prepared using conventional diluents or excipients (such as, but not limited to, sesame oil) and techniques known in the galenic art.Accordingly, oral dosage forms can include tablets, capsules, liquids, suspensions, etc.
[0210] The term "concurrently" when referring to therapeutic use means administration of two or more active ingredients to a patient as part of a treatment regimen for a disease or disorder, whether the two or more active agents are given at the same or different times, or by the same or different routes of administration. Concomitant administration of two or more active ingredients can be at different times on the same day, or on different days, or with different frequencies.
[0211] The term "simultaneously" when referring to therapeutic use means the administration of two or more active ingredients at the same time, or near the same time, by the same route of administration.
[0212] The term "separately" when referring to therapeutic uses means the administration of two or more active ingredients at the same time, or near the same time, by different routes of administration.
[0213] Method for preparing the disclosed compounds: Compounds of formula A and methods of synthesis thereof, including the synthesis of intermediates used in the synthetic scheme below, are disclosed, for example, in U.S. Pat. No. 8,309,722 and Published Patent Application No. 2017 / 319580. Synthesis of analogous fused γ-carbolines is disclosed, for example, in U.S. Pat. No. 8,309,722, U.S. Pat. No. 8,993,572, U.S. Pat. Appl. Publication No. 2017 / 0183350, WO 2018 / 126140 and WO 2018 / 126143, the contents of each of which are incorporated herein by reference in their entirety. Compounds of the present disclosure can be prepared using similar methods.
[0214] R 1 C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH2-OC(R a )(R b )(R c ) or -C(R 6 )(R 7 )-OC(O)-R 8 Compounds of the formula: can be prepared according to the procedures described in International Application PCT / US2018 / 043102.
[0215] Other compounds of the present disclosure can be prepared by analogous procedures known to those skilled in the art.
[0216] Diastereomers of the compounds of the present disclosure can be isolated or purified by conventional methods known in the art, such as column purification, preparative thin layer chromatography, preparative HPLC, crystallization, trituration, simulated moving bed technology, and the like.
[0217] Salts of the compounds of the present disclosure can be prepared similarly as disclosed in U.S. Pat. Nos. 6,548,493; 7,238,690; 6,552,017; 6,713,471; 7,183,282; 8,648,077; 9,199,995; 9,586,860; U.S. Reissue Patent No. 39680; and U.S. Reissue Patent No. 39679, the contents of each of which are incorporated herein by reference in their entirety.
[0218] The diastereomers of the compounds produced can be separated by HPLC, for example, using a CHIRALPAK® AY-H, 5μ, 30×250 mm column at room temperature and eluting with 10% ethanol / 90% hexane / 0.1% dimethylethylamine. Peaks can be detected at 230 nm to produce diastereomers with 98-99.9% ee. EXAMPLES
[0219] Example 1: Synthesis of (6bR,10aS)-8-(3-(4-fluorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one [ka]
[0220] A mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (100 mg, 0.436 mmol), 1-(3-chloroproxy)-4-fluorobenzene (100 μL, 0.65 mmol) and potassium iodide (KI) (144 mg, 0.87 mmol) in dimethylformamide (DMF) (2 mL) is degassed with argon for 3 minutes and N,N-diisopropylethylamine (DIPEA) (150 μL, 0.87 mmol) is added. The resulting mixture is heated to 78° C. and stirred at this temperature for 2 hours. The mixture is cooled to room temperature and then filtered. The filter cake is purified by silica gel column chromatography using a gradient of 0-100% ethyl acetate in methanol / 7N NH3 in methanol (1:0.1 v / v) mixture as eluent to give the partially purified product, which is further purified on a semi-preparative HPLC system using a gradient of 0-60% acetonitrile in water containing 0.1% formic acid over 16 min to give the title product as a solid (50 mg, 30% yield). MS (ESI) m / z 406.2 [M+1] + . 1 H NMR (500 MHz, DMSO-d6) δ 10.3 (s, 1H), 7.2 - 7.1 (m, 2H), 7.0 - 6.9 (m, 2H), 6.8 (dd, J = 1.03, 7.25 Hz, 1H), 6.6 (t, J = 7.55 Hz, 1H), 6.6 (dd, J = 1.07, 7.79 Hz, 1H), 4.0 (t, J = 6.35 Hz, 2H), 3.8 (d, J = 14.74 Hz, 1H), 3.3 - 3.2 (m, 3H), 2.9 (dd, J = 6.35, 11.13 Hz, 1H), 2.7 - 2.6 (m, 1H), 2.5 - 2.3 (m, 2H), 2.1 (t, J = 11.66 Hz, 1H), 2.0 (d, J = 14.50 Hz, 1H), 1.9 - 1.8 (m, 3H), 1.7 (t, J = 11.04 Hz, 1H).
[0221] Example 2: Synthesis of (6bR,10aS)-8-(3-(6-fluoro-1H-indazol-3-yl)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one [ka]
[0222] Step 1: To a stirred solution of BCl3·MeS (10.8 g, 60 mmol) in toluene at 0-5 °C, 3-fluoroaniline (5.6 mL, 58 mmol) is added, followed by 4-chlorobutyronitrile (7.12 g, 68.73 mmol) and aluminum chloride (AlCl3) (8.0 g, 60.01 mmol). The mixture is stirred at 130 °C overnight and cooled to 50 °C. Hydrochloric acid (3N, 30 mL) is carefully added and the resulting solution is stirred at 90 °C overnight. The resulting brown solution is cooled to room temperature and evaporated to dryness. The residue is dissolved in dichloromethane (DCM) (20 mL) and basified with saturated Na2CO3 to pH = 7-8. The organic phase is separated, dried over Na2CO3 and then concentrated. The residue is purified by silica gel column chromatography using a gradient of 0-20% ethyl acetate in hexane as eluent to give 2'-amino-4-chloro-4'-fluorobutyrophenone as a yellow solid (3.5 g, 28% yield). MS (ESI) m / z 216.1 [M+1] + .
[0223] Step 2: To a suspension of 2'-amino-4-chloro-4'-fluorobutyrophenone (680 mg, 3.2 mmol) in concentrated HCl (14 mL) at 0-5 °C is added NaNO2 (248 mg, 3.5 mmol) in water (3 mL). The resulting brown solution is stirred at 0-5 °C for 1 h, then SnCl2·2H2O (1.74 g, 7.7 mmol) in concentrated HCl (3 mL) is added. The mixture is stirred at 0-5 °C for an additional 1 h, then dichloromethane (30 mL) is added. The reaction mixture is filtered, the filtrate is dried over K2CO3 and evaporated to dryness. The residue is purified by silica gel column chromatography using a 0-35% ethyl acetate in hexane gradient as eluent to give 3-(3-chloropropyl)-6-fluoro-1H-indazole (400 mg, 60% yield) as a white solid. MS (ESI) m / z 213.1 [M+1] + .
[0224] Step 3: (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (100 mg, 0.436 mmol), 3-(3-chloropropyl)-6-fluoro-1H-indazole (124 mg, 0.65 mmol) and KI (144 mg, 0.87 mmol) are degassed with argon for 3 minutes and DIPEA (150 μL, 0.87 mmol) is added. The resulting mixture is stirred at 78 ° C for 2 hours and then cooled to room temperature. The resulting precipitate is filtered. The filter cake is purified on a semi-preparative HPLC system using a gradient of 0-60% acetonitrile in water containing 0.1% formic acid over 16 min to give (6bR,10aS)-8-(3-(6-fluoro-1H-indazol-3-yl)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one as an off-white solid (50 mg, 28% yield). MS (ESI) m / z 406.2 [M+1] + . 1H NMR (500 MHz, DMSO-d6) δ 12.7 (s, 1H), 10.3 (s, 1H), 7.8 (dd, J = 5.24, 8.76 Hz, 1H), 7.2 (dd, J = 2.19, 9.75 Hz, 1H), 6.9 (ddd, J = 2.22, 8.69, 9.41 Hz, 1H), 6.8 - 6.7 (m, 1H), 6.6 (t, J = 7.53 Hz, 1H), 6.6 (dd, J = 1.07, 7.83 Hz, 1H), 3.8 (d, J = 14.51 Hz, 1H), 3.3 - 3.2 (m, 1H), 3.2 (s, 2H), 2.9 (dt, J = 6.35, 14.79 Hz, 3H), 2.7 - 2.6 (m, 1H), 2.4 - 2.2 (m, 2H), 2.1 (t, J = 11.42 Hz, 1H), 2.0 - 1.8 (m, 3H), 1.8 - 1.7 (m, 1H), 1.7 (t, J = 10.89 Hz, 1H).
[0225] Example 3: Synthesis of (6bR,10aS)-8-(3-(6-fluorobenzo[d]isoxazol-3-yl)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one [ka]
[0226] A mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (148 mg, 0.65 mmol), 3-(3-chloropropyl)-6-fluorobenzo[d]isoxazole (276 mg, 1.3 mmol) and KI (210 mg, 1.3 mmol) is degassed with argon, then DIPEA (220 μL, 1.3 mmol) is added. The resulting mixture is stirred at 78° C. for 2 hours, then cooled to room temperature. The mixture is concentrated in vacuum. The residue is suspended in dichloromethane (50 mL) and then washed with water (20 mL). The organic phase is dried over K2CO3, filtered and then concentrated in vacuum. The crude product is purified by silica gel column chromatography using a gradient of 0-10% methanol in ethyl acetate containing 1% 7N NH3 to give the title product as a solid (80 mg, 30% yield). MS (ESI) m / z 407.2 [M+1] + . 1 H NMR (500 MHz, DMSO-d6) δ 10.3 (s, 1H), 8.0 - 7.9 (m, 1H), 7.7 (dd, J = 2.15, 9.19 Hz, 1H), 7.3 (td, J = 2.20, 9.09 Hz, 1H), 6.8 (d, J = 7.22 Hz, 1H), 6.6 (t, J = 7.54 Hz, 1H), 6.6 (d, J = 7.75 Hz, 1H), 3.8 (d, J = 14.53 Hz, 1H), 3.3 (s, 1H), 3.2 (s, 1H), 3.2 - 3.1 (m, 1H), 3.0 (t, J = 7.45 Hz, 2H), 2.9 - 2.8 (m, 1H), 2.7 - 2.5 (m, 1H), 2.4 - 2.2 (m, 2H), 2.2 - 2.0 (m, 1H), 2.0 - 1.8 (m, 3H), 1.8 - 1.6 (m, 2H).
[0227] Example 4: Synthesis of 4-(3-((6bR,10aS)-2-oxo-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]-pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)propoxy)benzonitrile [ka]
[0228] Step 1: A degassed suspension of ethyl (4aS,9bR)-6-bromo-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-carboxylate (21.5 g, 66.2 mmol), chloroacetamide (9.3 g, 100 mmol) and KI (17.7 g, 107 mmol) in dioxane (60 mL) is stirred at 104° C. for 48 hours. The solvent is removed and the residue is suspended in dichloromethane (200 mL) and extracted with water (100 mL). The separated dichloromethane phase is dried over potassium carbonate (K2CO3) for 1 hour and then filtered. The filtrate is evaporated to give the crude product as a brown oil. Ethyl acetate (100 mL) is added to the brown oil and the mixture is sonicated for 2 minutes. A yellow solid gradually precipitates from the mixture and returns to a gel after standing at room temperature for another 2 hours. Additional ethyl acetate (10 mL) is added and the resulting solid is filtered. The filter cake is rinsed with ethyl acetate (2 mL) and further dried under high vacuum to give ethyl (4aS,9bR)-5-(2-amino-2-oxoethyl)-6-bromo-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-carboxylate as an off-white solid (19 g, 75% yield). This product is used directly in the next step without further purification. MS (ESI) m / z 382.0 [M+H] + .
[0229] Step 2: A mixture of (4aS,9bR)-5-(2-amino-2-oxoethyl)-6-bromo-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-ethyl carboxylate (12.9 g, 33.7 mmol), KI (10.6 g, 63.8 mmol), CuI (1.34 g, 6.74 mmol) in dioxane (50 mL) is purged with argon for 5 min. To this mixture is added N,N,N,N'-tetramethylethylenediamine (3 mL) and the resulting suspension is stirred at 100 °C for 48 h. The reaction mixture is cooled to room temperature and poured onto a silica gel pad and filtered. The filter cake is rinsed with ethyl acetate (1 L x 2). The combined filtrate is concentrated to dryness to give the product (6bR,10aS)-2-oxo-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8-carboxylic acid ethyl ester as a white solid (8 g, 79% yield). MS (ESI) m / z 302.1 [M+H]+.
[0230] Step 3: (6bR,10aS)-2-oxo-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8-carboxylic acid ethyl ester (6.4 g, 21.2 mmol) is suspended in HBr / acetic acid solution (64 mL, 33% w / w) at room temperature. The mixture is heated at 50° C. for 16 hours. After cooling and treatment with ethyl acetate (300 mL), the mixture is filtered. The filter cake is washed with ethyl acetate (300 mL) and then dried under vacuum. The resulting HBr salt is then suspended in methanol (200 mL) and cooled with dry ice in isopropanol. Under vigorous stirring, ammonia solution (10 mL, 7N in methanol) is slowly added to the suspension to adjust the pH of the mixture to 10. The resulting mixture was dried in vacuum without further purification to give crude (6bR,10aS)-2-oxo-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline (8.0 g) which was used directly in the next step. MS (ESI) m / z 230.2 [M+H] + .
[0231] Step 4: A mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (100 mg, 0.436 mmol), 4-(3-bromopropoxy)benzonitrile (99 mg, 0.40 mmol) and KI (97 mg, 0.44 mmol) in DMF (2 mL) is purged with argon for 3 min and diisopropylethylamine (DIPEA) (80 μL, 0.44 mmol) is added. The resulting mixture is heated to 76 ° C and stirred at this temperature for 2 h. The solvent is removed and the residue is purified by silica gel column chromatography using a gradient of 0-100% mixed solvent [ethyl acetate / methanol / 7N NH3 (10:1:0.1 v / v)] in ethyl acetate to give the title product as a white foam (35 mg, 45% yield). MS (ESI) m / z 389.1 [M+1] + . 1 H NMR (500 MHz, DMSO-d6) δ 10.3 (s, 1H), 7.8 (d, J = 8.80 Hz, 2H), 7.1 (d, J = 8.79 Hz, 2H), 6.8 (d, J = 7.39 Hz, 1H), 6.6 (t, J = 7.55 Hz, 1H), 6.6 (d, J = 6.78 Hz, 1H), 4.1 (t, J = 6.36 Hz, 2H), 3.8 (d, J = 14.53 Hz, 1H), 3.3 - 3.2 (m, 3H), 3.0 - 2.8 (m, 1H), 2.7 - 2.6 (m, 1H), 2.5 - 2.3 (m, 2H), 2.2 - 2.0 (m, 1H), 2.0 - 1.8 (m, 3H), 1.8 - 1.7 (m, 1H), 1.7 (t, J = 11.00 Hz, 1H).
[0232] Example 5: Synthesis of (6bR,10aS)-8-(3-(4-chlorophenoxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one [ka]
[0233] To a degassed mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo-[1,2,3-de]quinoxalin-2(3H)-one (110 mg, 0.48 mmol), 1-(3-bromopropoxy)-4-chlorobenzene (122 mg, 0.49 mmol) and KI (120 mg, 0.72 mmol) in DMF (2.5 mL) is added DIPEA (100 μL, 0.57 mmol). The resulting mixture is heated to 76 °C and stirred at this temperature for 2 h. The solvent is removed and the residue is purified by silica gel column chromatography using a gradient of 0-100% mixed solvent [ethyl acetate / methanol / 7N NH3 (10:1:0.1 v / v)] in ethyl acetate. Obtain the title product as a white solid (41 mg, 43% yield). (ESI) m / z 398.1 [M+1] + . 1 H NMR (500 MHz, DMSO-d6) δ 10.3 (s, 1H), 7.4 - 7.2 (m, 2H), 6.9 (d, J = 8.90 Hz, 2H), 6.8 - 6.7 (m, 1H), 6.6 (t, J = 7.53 Hz, 1H), 6.6 (dd, J = 1.04, 7.80 Hz, 1H), 4.0 (t, J = 6.37 Hz, 2H), 3.8 (d, J = 14.53 Hz, 1H), 3.3 - 3.2 (m, 3H), 2.9 - 2.8 (m, 1H), 2.7 - 2.6 (m, 1H), 2.4 (ddt, J = 6.30, 12.61, 19.24 Hz, 2H), 2.1 - 2.0 (m, 1H), 2.0 - 1.9 (m, 1H), 1.9 - 1.7 (m, 3H), 1.7 (t, J = 10.98 Hz, 1H).
[0234] Example 6: Synthesis of (6bR,10aS)-8-(3-(quinolin-8-yloxy)propyl)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one [ka]
[0235] A mixture of (6bR,10aS)-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one (120 mg, 0.52 mmol), 8-(3-chloropropoxy)quinoline (110 mg, 0.50 mmol) and KI (120 mg, 0.72 mmol) in DMF (2.5 mL) is purged with argon for 3 min and DIPEA (100 μL, 0.57 mmol) is added. The resulting mixture is heated to 76 °C and stirred at this temperature for 2 h. The solvent is removed and the residue is suspended in dichloromethane (30 mL) and washed with water (10 mL). The dichloromethane phase is dried over K2CO3. The separated organic phase is evaporated to dryness. The residue is purified by silica gel column chromatography using a gradient of 0-100% mixed solvent [ethyl acetate / methanol / 7N NH3 (10:1:0.1 v / v)] in ethyl acetate to give the title product as a light brown solid (56 mg, 55% yield). (ESI) m / z 415.2 [M+1] + . 1H NMR (500 MHz, DMSO-d6) δ 10.1 (s, 1H), 8.9 (dd, J = 1.68, 4.25 Hz, 1H), 8.3 (dd, J = 1.71, 8.33 Hz, 1H), 7.7 - 7.5 (m, 3H), 7.3 (dd, J = 1.50, 7.44 Hz, 1H), 7.0 - 6.8 (m, 1H), 6.8 - 6.5 (m, 2H), 4.4 (t, J = 5.85 Hz, 2H), 3.9 (d, J = 14.55 Hz, 1H), 3.8 - 3.6 (m, 2H), 3.5 (s, 1H), 3.4 (d, J = 14.47 Hz, 1H), 2.9 (b, 1H), 2.3 (d, J = 23.61 Hz, 5H), 1.3 (d, J = 7.00 Hz, 3H).
[0236] Example 7: Receptor Binding Profile Receptor binding was determined for the compound of Example 1 (compound of formula A) and the compounds of Examples 2-6 using the procedures of the following publications, each of which is incorporated herein by reference in its entirety: 5-HT 2A :Bryant, HU et al. (1996), Life Sci., 15:1259-1268;D2:Hall, DA and Strange, PG (1997), Brit. J. Pharmacol., 121:731-736;D1:Zhou, QY et al. (1990), Nature, 347:76-80;SERT:ParkPark, YM et al. (1999), Anal. Biochem., 269:94-104; μ opiate receptor: Wang, JB et al. (1994), FEBS Lett., 338:217-222.
[0237] Generally, results are expressed as a percentage of control specific binding obtained in the presence of test compound:
number
number
[0238] I C 50 Values (concentration producing half-maximal inhibition of control specific binding) and Hill coefficients (nH) were calculated using Hill equation curve fitting:
number
number
[0239] The following receptor affinity results are obtained: [Table 1]
[0240] Additional compounds of formula I are prepared by procedures similar to those described in Examples 1-6. The receptor affinity results for these compounds are shown in the table below: [Table 2]
[0241] Example 8: DOI-induced head spasm model in mice R-(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) is an agonist of the serotonin 5-HT2 receptor family. When administered to mice, it produces a behavioral profile associated with high frequency of head twitches. The frequency of these head twitches during a given period can be taken as an estimate of 5-HT2 receptor agonism in the brain. Conversely, this behavioral assay can be used to determine 5-HT2 receptor antagonism in the brain by administering DOI with or without an antagonist and recording the reduction in DOI-induced head twitches following administration of the antagonist.
[0242] The method of Darmani et al., Pharmacol Biochem Behav. (1990) 36:901-906, the contents of which are incorporated herein by reference in their entirety, is used with minor modifications. (±)-DOI HCl is injected subcutaneously and the mice are immediately housed in conventional plastic cages. The number of head twitches is counted for 6 min starting 1 min after DOI administration. Test compounds are administered orally 0.5 h prior to DOI injection. The results are expressed as EC 50 The results are shown in the table below: [Table 3]
[0243] The results show that the compound of Example 1 potently blocks DOI head twitches and inhibits the in vitro 5-HT 2A It shows that the results are consistent.
[0244] Example 9: Mouse tail flick assay The mouse tail flick assay is a measurement of analgesia as indicated by the pain reflex threshold of restrained mice. Male CD-1 mice are placed with their tails under the focused beam of a high intensity infrared heat source, which heats the tail. The animal can withdraw its tail from the heat source at any time if it becomes uncomfortable. The amount of time between turning on the heating device and flicking the mouse's tail out of the path of the heat source (latency) is recorded. Administration of morphine produces analgesia, which causes a delay in the mouse's response to heat (increased latency). Preadministration of a morphine (MOR) antagonist, i.e., naloxone (NAL), reverses this effect, resulting in normal latencies. This test is used as a functional assay to measure antagonism of the μ-opiate receptor.
[0245] Example 9a: Antagonism of morphine-induced analgesia by the compound of Example 1 Ten male CD-1 mice (approximately 8 weeks old) are assigned to each of five treatment groups. Groups are treated as follows: Group (1) [negative control]: 0.25% methylcellulose vehicle is orally administered 60 min prior to the tail flick test and saline vehicle is orally administered 30 min prior to the tail flick test; Group (2) [positive control]: 0.25% methylcellulose vehicle is orally administered 60 min prior to the test and 5 mg / kg morphine in saline is orally administered 30 min prior to the test; Group (3) [positive control]: 3 mg / kg naloxone in saline is orally administered 50 min prior to the test and 5 mg / kg morphine in saline is orally administered 30 min prior to the test; Groups (4)-(6): 0.1 mg / kg, 0.3 mg / kg or 1 mg / kg of the test compound in 0.25% methylcellulose vehicle is orally administered 60 min prior to the test and 5 mg / kg morphine is orally administered 30 min prior to the test. The results are presented in the table below as mean latencies measured in seconds:
[0246] [Table 4]
[0247] The results demonstrate that the compound of Example 1 exerts a dose-dependent blockade of morphine-induced μ opiate receptor activity.
[0248] Example 9b: Analgesic effect of the compound of Example 1 inhibited by naloxone In a second study using the mouse tail flick assay described above, the compound of Example 1 is further compared at doses of 1.0 mg / kg, 3.0 mg / kg and 10 mg / kg to morphine at 5 mg / kg, with and without pretreatment with naloxone at 3 mg / kg (ip). In the pretreated groups, naloxone is administered 20 minutes prior to the tail flick test. In the non-pretreated controls, saline is administered 20 minutes prior to the tail flick test. In each group, vehicle, morphine or the compound of Example 1 is administered 30 minutes prior to the tail flick test. The results are presented in the table below as mean latency (seconds):
[0249] [Table 5]
[0250] It can be seen that administration of the compound of Example 1 at all doses significantly increases the latency to tail flick, and this effect is attenuated by pretreatment with naloxone.The results show that the compound of Example 1 produces a dose-dependent analgesic effect, and further suggest that this effect is mediated by μ-opioid receptor agonism.
[0251] Example 9c: Time course of analgesic activity, compound of Example 1 The tail flick assay described above is repeated to determine the time course of analgesia resulting from administration of the compound of Example 1. Mice are administered (1) vehicle 30 min prior to the assay, (2) 5 mg / kg morphine 30 min prior to the assay, or (3)-(7) 1 mg / kg of the compound of Example 3 subcutaneously 30 min, 2 hr, 4 hr, 8 hr, or 24 hr prior to the assay. The results are presented in the table below as mean latency (seconds):
[0252] [Table 6]
[0253] The results show that compound of Example 1 produces effective analgesia when administered 30 minutes or 2 hours before tail flick assay (ANOVA, P<0.001 vs. vehicle). When administered 4 hours, 8 hours or 24 hours before tail flick assay, 1 mg / kg compound of Example 1 does not produce analgesic effects that are significantly different from vehicle control. Thus, compound of Example 1 does not produce long-term analgesia, which means that compound of Example 1 has low abuse potential and low risk of drug-drug interactions compared to other opiate analgesics.
[0254] Example 9d: Analgesic effect of chronic administration of the compound of Example 1 The above tail flick assay is repeated using a test model in which animals receive a chronic treatment regimen for 14 days and then an acute treatment 30 minutes prior to the tail flick assay. Mice are divided into three major groups with six subgroups with 10 mice each. The three groups receive either (A) vehicle, (B) 0.3 mg / kg of the compound of Example 1, or (C) 3.0 mg / kg of the compound of Example 2 as chronic treatments. Additionally, each subgroup receives either (1) vehicle, or (2)-(6) 0.01, 0.03, 0.1, 0.3 or 1.0 mg / kg of the compound of Example 1 as acute treatments. All treatments are administered subcutaneously. The results are shown in the table below as mean latency (seconds) to tail flick:
[0255] [Table 7]
[0256] It can be seen that acute treatment with the compound of Example 1 at 0.1, 0.3 and 1.0 mg / kg produces a statistically significant dose-dependent analgesic effect compared to intragroup acute treatment with vehicle. This is true for each of the chronic groups (A), (B) and (C). Compared to pretreatment with vehicle, pretreatment with the compound of Example 1 at 0.3 mg / kg or 3.0 mg / kg generally shows a statistically significant decrease in tail flick latency when comparing the same acute treatment subgroups. These results indicate that after 14 days of chronic treatment, some tolerance occurs to the analgesic effect of the compound of Example 1, but the analgesic effect obtained remains effective despite chronic pretreatment.
[0257] Example 10: CNS Phosphoprotein Profile A comprehensive molecular phosphorylation study is also carried out to test the central nervous system (CNS) profile of the compound of Example 1. The degree of protein phosphorylation of selected important central nervous system proteins is measured in the nucleus accumbens of mice. The proteins tested include ERK1, ERK2, Glu1, NR2B and TH (tyrosine hydroxylase), and the compound of Example 1 is compared with the antipsychotic drugs risperidone and haloperidol.
[0258] Mice were treated with 3 mg / kg of the compound of Example 1 or 2 mg / kg of haloperidol. Mice were sacrificed 30 minutes to 2 hours after injection by focused whole brain microwave irradiation, and brain phosphoproteins were stored as they were present at the time of death. The nucleus accumbens was then dissected from each mouse brain, sliced, and frozen in liquid nitrogen. Samples were further prepared for phosphoprotein analysis by SDS-PAGE electrophoresis followed by phosphoprotein-specific immunoblotting as described in Zhu H, et al., Brain Res. 2010 Jun 25; 1342:11-23. Phosphorylation at each site was quantified, normalized to the total level of the protein (non-phosphorylated), and expressed as a percentage of the level of phosphate in vehicle-treated control mice.
[0259] The results show that, in contrast to haloperidol, which produces a greater than 400% increase in TH phosphorylation, and risperidone, which produces a greater than 500% increase, the compound of Example 1 has no significant effect on tyrosine hydroxylase phosphorylation at Ser40 at 30 and 60 minutes, indicating that the compounds of the present invention do not interfere with dopamine metabolism.
[0260] The results further show that the compound of Example 1 has no significant effect on NR2B phosphorylation at Tyr1472 at 30-60 minutes. The compound produces a slight increase in GluR1 phosphorylation at Ser845 and a slight decrease in ERK2 phosphorylation at Thr183 and Tyr185. Protein phosphorylation at various sites of specific proteins is known to be associated with various activities of cells, such as protein trafficking, ion channel activity, strength of synaptic signaling and changes in gene expression. Phosphorylation of Tyr1472 in NMDA glutamate receptors has been shown to be essential for the maintenance of neuropathic pain. Phosphorylation of Ser845 in GluR1 AMPA-type glutamate receptors is associated with several aspects of enhanced synaptic transmission and enhanced synaptic localization of the receptor, supporting long-term potentiation associated with cognitive performance. It has also been reported that phosphorylation of this residue increases the probability of channel opening. Phosphorylation of ERK2 kinase, a member of the MAP kinase cascade, at residues T183 and Y185 is required for full activation of this kinase, which is involved in many aspects of cell physiology, including regulation of cell proliferation, survival, and transcription. This kinase has been reported to be important in synapse formation and cognitive function.
[0261] Example 11: μ Opiate Receptor Activity Assay The compound of Example 1 is tested in CHO-K1 cells expressing hOP3 (human μ-opiate receptor μ1 subtype) using a HTRF-based cAMP assay kit (cAMP Dynamic2 Assay Kit from Cisbio, #62AM4PEB). Frozen cells are thawed in a 37°C water bath and resuspended in 10mL of Ham's F-12 medium containing 10% FBS. Cells are harvested by centrifugation and resuspended in assay buffer (5nM KCl, 1.25mM MgSO4, 124mM NaCl, 25mM HEPES, 13.3mM glucose, 1.25mM KH2PO4, 1.45mM CaCl2, 0.5g / L protease-free BSA, 1mM IBMX). Buprenorphine, a μ-opiate receptor partial agonist, and naloxone, a μ-opiate receptor antagonist, and DAMGO, a synthetic opioid peptide full agonist, are used as controls.
[0262] For agonist assays, 12 μL of cell suspension (2500 cells / well) is mixed with 6 μL of forskolin (final assay concentration 10 μM) in wells of a 384-well white plate, combined with 6 μL of increasing concentrations of test compound, and the plate is incubated at room temperature for 30 min. Lysis buffer is added and incubated for an additional hour before measuring cAMP concentrations according to the kit instructions. All assay points are measured in triplicate. Curve fitting is performed using XLfit software (IDBS) and EC values are calculated using a 4-parameter logistic fit. 50 The agonist assay measures the ability of a test compound to inhibit forskolin-stimulated cAMP accumulation.
[0263] For antagonist assays, 12 μL of cell suspension (2500 cells / well) is mixed with 6 μL of increasing concentrations of test compound, combined in wells of a 384-well white plate, and the plate is incubated at room temperature for 10 minutes. 2 -N-MePhe 4Six microliters of a mixture of 10-Gly-ol-enkepherin (final assay concentration 10 nM) and forskolin (final assay concentration 10 μM) is added and the plate is incubated for 30 minutes at room temperature. Lysis buffer is added and after a further hour of incubation, cAMP concentrations are measured according to the kit instructions. All assay points are measured in triplicate. Curve fitting is performed using XLfit software (IDBS) and ICs are calculated using a four-parameter logistic fit. 50 The apparent dissociation constant (K B The antagonist assay measures the ability of a test compound to reverse the inhibition of forskolin-induced cAMP accumulation caused by DAMGO.
[0264] The results are shown in the table below. The results show that the compound of Example 1 has a significantly higher IC 50 It has been shown to be a weak antagonist of the μ receptor, exhibiting moderately high affinity, but only about 22% agonist activity compared to DAMGO (compared to buprenorphine's activity of about 79% compared to DAMGO), and a partial agonist. The compound of Example 1 has also been shown to have moderately strong partial agonist activity.
[0265] [Table 8]
[0266] Buprenorphine is a drug used for chronic pain treatment and opiate withdrawal, but has the problem that users can become addicted due to its high partial agonist activity. To counter this, a commercial combination of buprenorphine and naloxone is used (sold as Suboxone). Without being bound by theory, it is believed that the compounds of the present invention, which are weaker partial μ agonists than buprenorphine and have some moderate antagonist activity, can more effectively treat patients with pain and / or opiate withdrawal, with a lower risk of addiction.
[0267] Additional related studies using recombinant human MOP-β-arrestin signaling pathways demonstrated that the compound of Example 1 does not stimulate β-arrestin signaling through the MOP receptor at concentrations up to 10 μM, but does not stimulate β-arrestin signaling through the MOP receptor at IC 50 It has been found to be an antagonist with an EC of 0.189 μM. In contrast, the full opioid agonist Met-enkephalin has an EC of 0.08 μM. 50 stimulates β-arrestin signaling.
[0268] Example 12: Rat Tolerance / Dependence Studies The compound of Example 1 is evaluated during repeated (28 days) daily subcutaneous administration to male Sprague-Dawley rats to monitor drug effects on dosing and to determine whether pharmacological tolerance occurs. Additionally, behavioral, physical and physiological signs of the rats are monitored after abrupt cessation of repeated administration to determine whether the compound induces physical dependence to withdrawal. Pharmacological studies are also performed in parallel with the tolerance and dependence studies to determine plasma drug exposure levels of the compound at the specific doses used in the tolerance and dependence studies. Morphine is used as a positive control to ensure the validity of the model and as a reference control drug from a similar pharmacological class.
[0269] The compound of Example 1 is evaluated at two doses, 0.3 and 3 mg / kg, administered subcutaneously four times daily. Repeated dosing is found to produce peak plasma concentrations of 15-38 ng / mL (mean, n=3) at 0.3 mg / kg and 70-90 ng / mL (mean, n=3) at 3 mg / kg. Peak concentrations are reached 30 minutes to 1.5 hours after dosing, with comparable results obtained on days 1, 14, and 28 of dosing.
[0270] It is found that both doses of the compound of Example 1 have no significant effect on the body weight, food and water intake, or body temperature of animals during either the administration or withdrawal period.The main behavioral and physical effects caused by repeated administration at 0.3mg / kg are hunched posture, Straub tail, and piloerection during the administration period.At higher doses, the main behavioral and physical signs observed are hunched posture, subdued behavior, Straub tail, tail rattle, and piloerection.
[0271] A similar profile of behavioral and physical signs is observed after abrupt cessation of the compound on day 28 of the study. No rearing and increased body tone are observed during the dosing period at 0.3 mg / kg, but are found to increase significantly during the withdrawal phase. At the higher doses, mild rearing is observed during the dosing period, but more pronounced rearing and increased body tone are observed during the withdrawal phase.
[0272] As a positive control, morphine is administered orally at 30 mg / kg twice daily. This dosing regimen is observed to be associated with changes in body weight, food and water intake, rectal temperature, and clinical signs consistent with the development of tolerance and withdrawal-induced dependence, as expected. Body weight was significantly increased compared to the vehicle-treated control group on days 2 and 3, but was significantly decreased on day 5. Morphine significantly reduced food intake on days 1-9. Thereafter, food intake is generally observed to be less than the control group, but was not significantly different from controls on days 9, 13, 14, 16, 18, 21, 22, and 25. These effects on body weight and food intake indicate tolerance to the effects of morphine.
[0273] Water intake in the morphine-treated group is also found to be significantly lower than the control group on 25 of the 28 days during the treatment period. Body temperature is also generally significantly lower than the control group during the treatment period, most notably on days 20, 21 and 27. The main behavioral effects induced by morphine during the treatment period are observed to be Straub's tail, jumping, digging, increased body tone, increased locomotor activity, explosive movement and exopthalmus.
[0274] Furthermore, withdrawal of morphine on day 28 results in an initial further decrease in food intake, followed by rebound hyperphagia, with food intake observed to be significantly increased on day 33 compared to the control group. Food intake returns to control levels by day 35. Similarly, rats previously administered morphine also show an initial decrease in water intake on day 29, followed by rebound hyperdipsia (water consumption returns to control levels by day 31). Furthermore, a statistically significant decrease in rectal body temperature is observed during administration, but body temperature returns to control levels during the withdrawal phase.
[0275] Furthermore, new behavioral and physical signs were observed during the withdrawal phase from morphine, indicating the presence of dependence. These signs included piloerection, ataxia / rolling gait, wet dog shakes, and pinched abdomen. Other abnormal behaviors observed during the administration phase gradually disappeared during the withdrawal phase. By day 35, rearing was the only behavioral or physical sign observed with high incidence in rats previously administered morphine.
[0276] Thus, repeated administration of morphine is shown to produce clear signs of tolerance and dependence in this study, with changes in body weight, food and water intake, rectal temperature, and clinical signs consistent with the development of tolerance and withdrawal-induced dependence, demonstrating the relevance of the study method in detecting physiological changes during and after administration.
[0277] In contrast, four repeated doses of the compound of Example 1, both at 0.3 and 3 mg / kg, do not induce tolerance during 28 days of subcutaneous administration. Furthermore, at higher doses, a similar but reduced profile of behavioral and physical signs is observed upon withdrawal, which is not considered to be of clinical significance. Overall, therefore, the compound of Example 1 has been found not to induce a physical dependence syndrome upon cessation of administration.
[0278] Example 13: Oxycodone Dependence Withdrawal Study in Mice Oxycodone is administered to male C57BL / 6J mice in an escalating dose regimen of 9, 17.8, 23.7, and 33 mg / kg bid (7 hours between injections) on days 1-2, 3-4, 5-6, and 7-8, respectively, for 8 days. On the morning of day 9, mice are administered either 0.3, 1, or 3 mg / kg of the compound of Example 1 subcutaneously. Thirty minutes later, an injection of vehicle or an injection of 3 mg / kg of naloxone is administered. Another cohort of mice serves as negative controls, and these mice are administered saline on days 1-8 instead of oxycodone. On day 9, these mice are administered either vehicle (as above, followed by naloxone) or 3 mg / kg (sc) of the compound of Example 1 (as above, followed by naloxone).
[0279] On the 9th day, immediately after injection of naloxone (or vehicle), mice are individually housed in transparent plastic cages and observed continuously for 30 min. Mice are monitored for typical physical signs of opiate withdrawal, including jumping, violent shaking, paw tremors, backing, ptosis and diarrhea. All such behaviors are recorded as new occurrences if they are separated by at least 1 s or are interrupted by normal behavior. Animal weights are also recorded immediately before and 30 min after naloxone (or vehicle) injection. Data are analyzed by ANOVA, where appropriate, followed by Tukey's test for multiple comparisons. Significance levels are established at p<0.05.
[0280] The results are shown in the table below: [Table 9]
[0281] The total number of symptoms includes leg tremors, jumping, and violent tremors. It can be seen that naloxone induces significant total number of symptoms, leg tremors, jumping, and body weight change (p≦0.0001 for each) in oxycodone-treated mice. The compound of Example 1 causes a significant reduction in total number of symptoms and leg tremors at all doses tested. In addition, the compound also causes a significant reduction in jumping and attenuated body weight loss at 3.0 mg / kg.
[0282] These results demonstrate that the compound of Example 1 dose-dependently reduces the signs and symptoms of opiate withdrawal following abrupt cessation of opiate administration in opiate-dependent rats.
[0283] Example 14: Formalin Paw Test (Inflammatory Pain Model) Subplantar administration of a chemical stimuli such as formalin causes immediate pain and discomfort in mice, followed by inflammation. Subcutaneous injection of a 2.5% formalin solution (37 wt% aqueous formaldehyde solution, diluted with saline) into the hind paw produces a biphasic response: an acute pain response and a delayed inflammatory response. Thus, this animal model provides information on both acute and subacute / tonic pain in the same animal.
[0284] C57 mice are habituated in the observation chamber. Thirty minutes before formalin administration, mice are administered vehicle by subcutaneous injection, 5 mg / kg morphine (in saline) by subcutaneous injection, or 0.3, 1.0 or 3.0 mg / kg of the compound of Example 1 (in 45% w / v aqueous cyclodextrin solution) by subcutaneous injection. In addition, another set of mice is treated with control vehicle or 3.0 mg / kg of the compound of Example 1 by oral administration instead of subcutaneous injection.
[0285] Mice are then injected subcutaneously with 20 μL of 2.5% formalin solution into the plantar surface of the left hind paw. Over the next 40 min, the total time spent licking or biting the treated hind paw is recorded. The first 10 min represents the acute nociceptive response, while the latter 30 min represents the delayed inflammatory response. At 1 min intervals, the behavior of each animal is assessed using a "Mean Behavioral Rating" scored on a scale of 0 to 4: 0: No reaction, animal asleep 1: The animal walks nimbly on the treated leg, e.g. on its toes 2: The animal is holding up the treated paw 3: The animal is shaking the treated paw 4: Animal licking or biting the treated paw Data are analyzed by ANOVA, where appropriate, followed by post-hoc comparisons using Fisher's test. Significance is established at p<0.05.
[0286] The results are shown in the table below. [Table 10]
[0287] The results show significant treatment effects during both the early (0-10 min) and late (11-40 min) phases of the response. Post-hoc comparisons show that subcutaneous injection of morphine or compound of Example 1 (3 mg / kg) significantly attenuates the pain behavior ratings evoked by formalin injection and significantly reduces licking time compared to vehicle treatment. Post-hoc comparisons also show that subcutaneous injection of morphine or compound of Example 1 (3 mg / kg) and oral administration of compound of Example 1 (3 mg / kg) significantly reduces the time spent licking. The mean pain behavior ratings were also reduced with the subcutaneous use of 1.0 mg / kg compound and with the oral use of 3.0 mg / kg compound, although these effects were not statistically significant in this study. The subcutaneous use of compound of Example 1 at 1.0 mg / kg reduced licking time as well, but the results were not statistically significant in this study. It was found that no mice in the study groups underwent significant changes in body weight.
[0288] Example 15: Self-administration in heroin-maintained rats Studies were conducted to determine whether heroin-addicted rats would self-administer the compound of Example 1 and found that they did not, further highlighting the non-addictive nature of the compounds of the present disclosure.
[0289] The study is conducted in three phases. In the first phase, rats are first trained to press a lever for food, then an intravenous jugular catheter is placed and they are trained to self-administer heroin. In response to a cue (illumination of a light in the cage), the animal presses the lever three times, resulting in one injection of heroin through the catheter. Heroin is provided at an initial dose of 0.05 mg / kg / injection, which is then increased to 0.015 mg / kg / injection. This trained response is then extinguished by replacing the heroin supply with saline. In the second phase, the saline solution is replaced by a solution of the compound of Example 1 at one of four doses: 0.0003 mg / kg / injection, 0.001 mg / kg / injection, 0.003 mg / kg / injection and 0.010 mg / kg / injection. Individual mice are administered one or two doses of the compound in an ascending fashion. This response is then abolished with an injection of saline, followed by a third phase in which heroin use is repeated at 0.015 mg / kg / injection. The purpose of the third phase is to demonstrate that at the end of the study the rats still exhibit addictive behavior to heroin. The results of the study are shown in the table below:
[0290] [Table 11]
[0291] The results show that rats showed a statistically significant increase in lever pressing when administered heroin, but no significant difference when administered saline or the compound of Example 1. Thus, the results suggest that rats do not become addicted to the compound of Example 1.
[0292] It should be noted that the study uses the term "reinstatement" to indicate that rats that were not interested in self-administering the compound of Example 1 will self-administer heroin if heroin is made available. Thus, "reinstatement" here means that the animals retain the ability or training to self-administer heroin intravenously. However, the results of this study show that rats in this situation do not choose to self-administer the compound of Example 1, indicating that the compound is not psychologically rewarding (i.e., not psychologically addictive).
[0293] Example 16: Rat model of neuropathic pain The compound of Example 1 is also tested in the STZ-rat model of neuropathic pain. Briefly, adult female rats are made diabetic by treatment with streptozotocin (STZ), an alkylating neoplastic agent that is toxic specifically to the insulin-producing beta cells of the pancreas. The resulting type I diabetes in the rats leads to the development of diabetic neuropathy over a period of 3-6 weeks. This can be demonstrated using various indices of painful neuropathy such as allodynia to light touch, hyperalgesia to pressure, cold and chemical stimuli. Once diabetic neuropathy is induced, the rats can be treated to examine the analgesic effects of the compound.
[0294] Paw tactile response threshold is a clinical assessment of allodynia to light touch. It can be measured using manual von Frey filaments (as described in Otto et al., Pain, 101:187-92 (2003)). A series of von Frey filaments of increasing logarithmic stiffness are used and the rat's response to each filament is observed. The results are used to calculate the 50% withdrawal threshold (the amount of filament stiffness that results in a 50% probability of the rat withdrawing its paw).
[0295] The paw mechanical response threshold is also a clinical assessment of allodynia to light touch, but relies on the observed response to pressure (force) applied to the paw.
[0296] Paw cold response threshold is a clinical assessment of cold pain perception. A hard filament equipped with a thermoelectric cooling system is used to stimulate the plantar surface of the hind paw for 5 seconds. The stimulation is repeated 10 times at intervals of 2-5 minutes. The number of paw withdrawal responses is recorded and converted into a numerical value (%) of response frequency. This procedure is repeated at various temperatures. It can be seen that in diabetic rats, below a certain threshold temperature, an enhanced (hyperalgesic) response to cold is observed. It can be seen that at stimulation temperatures of 20°C or 15°C, the response frequency is virtually the same between STZ-treated and control rats (about 10-20% of the response). In contrast, at stimulation temperatures below 10°C, there is a substantial divergence of the frequency response. In control rats, a stimulation temperature of 10°C results in a response frequency of about 10%, whereas at 5°C this increases to a response frequency of about 40%. In contrast, STZ-treated rats show a response frequency of about 60% at 10°C and about 80% at 5°C. This indicates that STZ-treated rats suffer from cold hyperalgesia at temperatures below 10° C. Stable cold allodynia responses are observed 4–12 weeks after the induction of diabetes.
[0297] Example 16a: The compound of Example 1 inhibits cold allodynia responses Six groups of rats are compared over a 6-hour period following injection (subcutaneous injection) of the compound of Example 1 ("Compound") or vehicle: (1) vehicle-injected control rats, (2) 10 mg / kg compound-injected control rats, (3) vehicle-injected STZ-diabetic rats, (4) 1 mg / kg compound-injected STZ-diabetic rats, (5) 3 mg / kg compound-injected STZ-diabetic rats, and (6) 10 mg / kg compound-injected STZ-diabetic rats. Cold allodynia response testing is performed at 0, 1, 2, 4, and 6 hours as described above, using a stimulus temperature of 10°C. The injection vehicle is pure polyethylene glycol-400 (PEG400).
[0298] Results show that control groups rats (1) and (2) show a response frequency of 10-30% at all time points (normal cold response). Group (3) positive vehicle control rats show a response frequency of 70-90% at all time points, indicating cold allodynia. Comparison of groups (4)-(6) shows a dose-dependent reduction in cold allodynia. At 1 mg / kg (group (4)), the compound reduces response frequency to near normal (~35% response) at 1 hour, which decays to about 70% at 4 hours and about 75% at 6 hours. At 3 mg / kg (group (5)), the compound reduces response frequency to normal levels (~10% response) at 1 hour, which decays to about 65% at 4 hours and about 75% at 6 hours. At 10 mg / kg (Group (6)), the compound reduced response frequency to the normal range at 1 hour (approximately 15%), remained in the normal range at 2 and 4 hours (approximately 10% at 2 hours and approximately 20% at 4 hours), and only increased to approximately 40% at 6 hours.
[0299] Rats are also tested in the rotorod motor coordination model at a dose of 3mg / kg, and no motor coordination loss is found to be caused by this compound.This further supports that the cold allodynia observations are not due to the delayed motor response to cold stimulation, but due to pain inhibition.Interestingly, the time frame of the duration of action of subcutaneous injection of this compound is consistent with the results obtained in mouse tail flick assay (Example 9c).
[0300] Example 16b: The compound of Example 1 suppresses hyperalgesia to tactile stimuli Similar to the observations described in Example 16a, STZ-treated diabetic rats, when tested 4 to 12 weeks after induction of diabetes, exhibit stable tactile hyperalgesia, as measured after manual application of von Frey filaments.
[0301] The rats are divided into six groups as described in Example 16a and monitored for six hours after administration of the compound of Example 1 or vehicle. The test is performed using von Frey filaments as described above.
[0302] The results show that both control animals in groups (1) and (2) show a 50% withdrawal threshold of 8-14 grams, which is within the normal range. In contrast, animals in the positive vehicle control group (3) show a much lower 50% withdrawal threshold of 2-3 grams. Comparison of groups (4)-(6) shows a dose-dependent increase in the 50% withdrawal threshold to tactile stimulation. Consistent with the results of Example 16a, at a dose of 1 mg / kg the compound produces a moderate increase in threshold (peak threshold of about 4 g at 4 hours, declining to about 3 g at 6 hours). At a dose of 3 mg / kg the increase in withdrawal threshold is significantly greater, rising to about 6 g at 1 hour, peaking at about 8 g at 2 hours, and then declining to about 3 g at 4 hours. At a dose of 10 mg / kg the increase in withdrawal threshold is much greater, reaching the range observed in control animals. 10 mg / kg of the compound results in a threshold of about 9 g at 1 hour, peaking at about 10 g at 2 hours, then decreasing to about 7 g at 4 hours and about 3 g at 6 hours.
[0303] Example 16c: The compound of Example 1 inhibits hyperalgesia in response to mechanical (pressure) stimuli Rats are divided into six groups as described in Example 16a and monitored for six hours after administration of the compound of Example 1 or vehicle. The test is performed by measuring the static applied force threshold (pressure) for paw movement as described above.
[0304] The results show that both control animals in groups (1) and (2) exhibit withdrawal thresholds of 55-70 grams, which is within the normal range. In contrast, animals in the positive vehicle control group (3) exhibit a much lower withdrawal threshold of 20-30 grams. Comparison of groups (4)-(6) shows a dose-dependent increase in withdrawal threshold to mechanical stimulation. Consistent with the results of Examples 16a and 16b, at a dose of 1 mg / kg, the compound produces a moderate increase in threshold (peak threshold of about 40 g at 4 hours, declining to about 35 g at 6 hours). At a dose of 3 mg / kg, the increase in withdrawal threshold is greater, peaking at about 45 g at 2 hours, but then declining to about 25 g at 6 hours. However, at a dose of 10 mg / kg, the increase in withdrawal threshold is greater and more sustained, reaching the range observed in control animals. At 10 mg / kg of the compound, the threshold is approximately 60 g at 1 hour, which decreases to 45-50 g at 2-4 hours, and then decreases to approximately 35 g at 6 hours.
[0305] Example 17: Animal Pharmacokinetic Data The pharmacokinetic profile of the compound of Example 1 is studied in several animals using standard procedures.
[0306] Example 17a: Rat PK studies In the first study, rats are dosed with the compound of Example 1 either intravenously (IV) at 1 mg / kg in a 45% Trapposol vehicle or orally (PO) at 10 mg / kg in a 0.5% CMC vehicle (N=3 per group). In the second study, rats are dosed with the compound of Example 1 either PO at 10 mg / kg or subcutaneously (SC) at 3 mg / kg in a 45% Trapposol vehicle (N=6 per group). Plasma concentrations of the drug are measured at 0-48 hours after dosing. Representative results are shown in the table below (* indicates plasma concentrations below measurable quantification levels):
[0307] [Table 12]
[0308] Example 17b: Mouse PK studies A similar study is performed in mice using a 10 mg / kg PO dose of the compound of Example 1, with the following results: Tmax=0.25 hours; Cmax=279 ng / mL; AUC(0-4h)=759 ng·hr / mL; blood-plasma ratios (0.25-4h) ranging from 3.7 to 6.6. The study is also performed at a dose of 0.1 mg / kg SC. Representative results are shown in the table below:
[0309] [Table 13]
[0310] Taken together, these results indicate that the compound of Example 1 is well absorbed, distributed to the brain and tissues, and retained with a reasonably long half-life to allow for once-daily administration of therapeutic doses.
[0311] Example 18: Zucker Fatty Diabetic Rat Model of Neuropathic Pain Insulin-resistant diabetes occurs spontaneously in Zucker Fatty Diabetic (ZFD) rats. These rats exhibit stable hyperglycemia and painful neuropathy that develops over several weeks. Painful neuropathy can be measured in rats using a variety of tests, including assays of paw touch and pressure responses, and heat (cold) thresholds. These tests can be used to measure the potential analgesic effects of therapeutics in development.
[0312] These experiments evaluate the effect of the compound of Example 1 on pain threshold in ZFD diabetic rats. The compound of Example 1 is formulated for subcutaneous (sc) or intrathecal (it) administration in 10% Trappsol (β-cyclodextrin) in water with 1% Tween-80 added to form a clear solution.
[0313] These experiments use 40 adult male Sprague-Dawley rats weighing 225-275 g at the start of the study, including 10 lean control rats and 30 ZFD rats. Animals are maintained in a vivarium under fluorescent lighting with a 12-hour light-dark cycle each day, at a controlled room temperature of 65-85°F and 30-70% relative humidity. All animals are kept two per cage and have free access to dry food and water.
[0314] Male ZFD rats are allowed to develop insulin-resistant diabetes. Hypoglycemia is confirmed using a strip-operated reflectometer in blood samples obtained by tail puncture after 4 days and at the time of death. All animals are observed daily for the duration of the study. Body weights and plasma glucose concentrations are measured at the end of the study.
[0315] Paw tactile response threshold: This test reproduces the clinical assessment of allodynia to light touch as detected using von Frey filaments and serves as the standard assay for the detection of allodynia that develops within 2-4 weeks of diabetes emergence in ZFD diabetic rats. The current method is described in detail in Calcutt, NC, Modeling Diabetic Sensory Neuropathy in Rats, METHODS IN MOLECULAR MEDICINE 99: 55-65 (2004).
[0316] Paw pressure response threshold: This test applies a greater force to the plantar hindpaw than the manual von Frey filaments and may be comparable to pressure-induced pain as described by diabetic subjects during standing and walking. Hyperalgesia to this measure develops over several weeks in ZFD rats, so this test can provide a different assessment of hyperalgesia and drug efficacy than allodynia measured with manual von Frey filaments. This method is described in detail in Lee-Kubil, Mixcoati-Zecuatl, Jolivalt, & Calcutt, Animal Models of Diabetes-Induced Neuropathic Pain, CURRENT TOPICS IN BEHAVIORAL NEUROSCIENCES 20: 147-170 (2014).
[0317] Paw cold response threshold: This test replicates the cold pain threshold clinical test. Rats are transferred to a wire-bottom testing cage and allowed to acclimate. The plantar surface of the hind paw is stimulated for 5 seconds with a hard filament attached to a Peltier thermoelectric cooling system. Stimulation is repeated 10 times with 2-5 minute intervals between stimulations and the number of paw withdrawal responses recorded and converted to response frequency (%). This paradigm is repeated at various stimulus temperatures. ZFD diabetic rats develop cold hyperalgesia at temperatures below 10°C, but normal response frequencies at higher temperatures confirm that this does not represent an exaggerated response to the applied pressure itself (see Table 18-1 below).
[0318] Formalin paw test: This test can distinguish pain resulting from primary afferent input (phase 1) from pain resulting from spinal sensitization and amplification of primary afferent input (phase 2). However, there is no clinical equivalent to this test. The method used here is described in detail in Calcutt (2004) supra.
[0319] Administration Procedure. Zucker fatty diabetic rats have been found to develop hyperglycemia over a period of 6-8 weeks. After confirmation of hyperglycemia, rats are examined weekly until baseline measurements indicate the development of stable allodynia / hyperalgesia (weeks 3-6 of diabetes). Once the presence of painful neuropathy is confirmed, rats are tested for three measures of hyperalgesia: cold allodynia threshold, tactile hyperalgesia (von Frey filaments), and pressure response measured by a mechanical von Frey device. All rats are tested in all three assays, and all rats receive each of the four pretreatments administered subcutaneously (sc) in a vehicle of 10% Trappsol in water. All rats receive treatments in the same order as follows: vehicle, 1 mg / kg of compound of Example 1, 3 mg / kg of compound of Example 1, and 10 mg / kg of compound of Example 1. Rats receive pretreatments 30 minutes prior to the start of testing. Measures of hyperalgesia / allodynia are recorded from each rat at baseline (0 hours), then 1, 2, 3, 4 and 6 hours after treatment.
[0320] After completion of testing of all rats at all doses / conditions for each assay (cold response, touch response and pressure response), rats are cannulated for intrathecal (it) application of vehicle or the compound of Example 1 (1 μg, 3 μg or 10 μg) directly to the spinal cord. All rats are then retested in each of the tree assays at each of the four pretreatment conditions / doses.
[0321] Statistical analysis. Data from the cold allodynia test using sc administration are analyzed using MANOVA for repeated measures over time performed by group and baseline for each dose. MANOVA is also performed by dose and baseline for the ZFD rats + compound of Example 1 group (no vehicle at 0 dose level). Two-way t-tests for the ZFD group at each time point and two-way t-tests for the ZFD group for change from baseline at each time point are performed. Data from the manual von Frey test are analyzed using chi-square analysis for responders. For data from the electrical von Frey test, one-way ANOVA is performed for all groups, followed by MANOVA (repeated measures ~ time) analysis by group and baseline for each dose and ZFD + compound of Example 1 group (no vehicle for 0 dose level). Two-way t-tests are performed for the response of the ZFD group at each time point and for the ZFD group for change from baseline at each time point.
[0322] Cold allodynia. ZFD rats show robust response frequency to paw presentation of a cold (10° C.) probe. Administering the compound of Example 1 sc to rats in 10% Trappsol vehicle (in water) dose-dependently reduces response frequency (%) (Table 18-1) ["Control" refers to Sprague-Dawley lean control rats, and "ZFD" refers to Zucker fatty diabetic rats]. Doses of 3 mg / kg and 10 mg / kg of the compound of Example 1 significantly reduce response frequency after treatment. It treatment of these rats with the compound of Example 1 also significantly reduces response frequency (%) at doses of 1 μg and 3 μg; at 1 μg the difference from vehicle is significant, while at 3 μg the difference from vehicle is significant at 1, 2, and 4 hours (Table 18-2).
[0323] [Table 14]
[0324] Manual von Frey (tactile) ZFD rats show a strong response to manual von Frey filament paw presentation, measured by a decrease in paw withdrawal threshold. Sc administration of the compound of Example 1 to rats in 10% Trappsol vehicle (in water) dose-dependently decreases paw withdrawal threshold (Table 18-3). A dose of 3 mg / kg of the compound of Example 1 results in a significant normalization of paw withdrawal threshold evident at 1 and 2 hours after treatment; a dose of 10 mg / kg induces a significant difference from vehicle at 1, 2 and 4 hours. It treatment of these rats with the compound of Example 1 also significantly normalizes threshold at the 1 μg dose level (Table 18-4).
[0325] [Table 15]
[0326] Paw pressure response. ZFD rats show a strong response frequency to paw presentation of mechanical von Frey filaments. Example 1 compound administered sc to rats in 10% Trappsol vehicle (in water) dose-dependently reduces response frequency (%) (Table 18-5). Example 1 compound at a dose of 3 mg / kg significantly reduces response frequency at 1 and 2 hours after treatment; 10 mg / kg induces a significant improvement in pain response at 1, 2, 4 and 6 hours. It treatment of these rats with Example 1 compound significantly reduces response frequency (%) at 1 μg (2 and 4 hours) and 3 μg (1, 2 and 4 hours) compared to vehicle (Table 18-6).
[0327] [Table 16]
[0328] Formalin Test. The compound of Example 1 administered either sc or it does not affect pain responses in either the early or late phase of the formalin test when administered at the end of the test.
[0329] Zucker fatty diabetic rats develop a stable and intensely painful neuropathic pain response that lasts for several months. These rats show a marked increase in cold allodynia, as well as a decrease in pain threshold in the tests of tactile and pressure hyperalgesia assays. Compound of Example 1 (free base) administered either sc or it significantly attenuates painful neuropathy in all three tests. Demonstration that similar results are obtained sc or it indicates that this effect is not simply a peripherally mediated effect. The data support the conclusion that compound of Example 1 attenuates painful neuropathic pain responses in rats sustaining insulin-deficient diabetes. The present application also includes the following aspects. [Aspect 1] A method for treating chronic and / or neuropathic pain, comprising administering to a patient in need of such treatment a compound of formula I: [ka] [In the formula, R 1 , H, C 1-6 Alkyl, -C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH 2 -OC(R a )(R b )(R c ) or -C(R 6 )(R 7 )-OC(O)-R 8 and; R 2 and R 3 are independently H, D, and C 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; L is for C 1-6 Alkylene (e.g., ethylene, propylene or butylene), C 1-6 Alkoxy (e.g., propoxy or butoxy), C 2-3 Alkoxy C 1-3 Alkylene (e.g., -CH 2 CH 2 OCH 2 -)、C 1-6 Alkylamino or NC 1-6 Alkyl C 1-6 Alkylamino (e.g., propylamino or N-methylpropylamino), C 1-6 Alkylthio (e.g., -CH 2 CH 2 CH 2 S-), C 1-6 Alkylsulfonyl (e.g., -CH 2 CH 2 CH 2 S(O) 2 -), each of which contains one or more R 4 may be substituted with a moiety; Each R 4 is independently 1-6 Alkyl (e.g., methyl), C 1-6 selected from alkoxy (e.g., methoxy), halo (e.g., F), cyano, or hydroxy; Z is selected from aryl (e.g., phenyl) and heteroaryl (e.g., pyridyl, indazolyl, benzimidazolyl, benzisoxazolyl), where the aryl or heteroaryl is selected from one or more R 4 may be substituted with a moiety; R 8 is -C(R a )(R b )(R c ), -OC(R a )(R b )(R c ), or -N(R d )(R e ) and; R a 、R b and R c are each independently H and C 1-24 alkyl; R d and R e are each independently H and C 1-24 alkyl; R 6 and R 7 are each independently H, C 1-6 Alkyl, carboxy and C 1-6 alkoxycarbonyl] The method includes administering a compound represented by the formula: The pain is caused by a peripheral neuropathy (e.g., mononeuropathy, plexopathy, radiculopathy, or polyneuropathy) or by a central neuropathy (e.g., deafferented pain or sympathetically maintained pain, e.g., complex regional pain syndrome (CRPS)); method. [Aspect 2] R 1 The method of embodiment 1, comprising a compound of formula I, wherein [Aspect 3] R 1 C 1-6 The method of embodiment 1, comprising a compound of formula I, which is alkyl, e.g., methyl. [Aspect 4] R 1 But -C(O)-OC(R a )(R b )(R c ), -C(O)-O-CH 2 -OC(R a )(R b )(R c ) or -C(R 6 )(R 7 )-OC(O)-R 8 The method of embodiment 1, comprising a compound of formula I, [Aspect 5] L is unsubstituted C 1-6 alkylene (e.g., ethylene, propylene, or butylene) or L is one or more R 4 C substituted with moiety 1-6 The method of any one of embodiments 1-4, comprising a compound of formula I that is an alkylene (eg, ethylene, propylene, or butylene). [Aspect 6] L is unsubstituted C 1-6 alkoxy (e.g., propoxy or butoxy) or L is one or more R 4 C substituted with moiety 1-6 The method of any one of embodiments 1-4, comprising a compound of Formula I that is alkoxy (eg, propoxy or butoxy). [Aspect 7] R 1 、R 2 and R 3 The method of any one of embodiments 1-6, comprising a compound of Formula I, wherein each is H. [Aspect 8] R with 1 or more Zs 4 The method of any one of aspects 1-7, comprising a compound of Formula I, which is an optionally substituted aryl (eg, phenyl) moiety. [Aspect 9] Z is one R selected from halo (e.g., fluoro, chloro, bromo, or iodo) and cyano. 4 The method of any one of embodiments 1-7, comprising a compound of Formula I, wherein Z is phenyl substituted with a moiety (eg, Z is 4-fluorophenyl, or 4-chlorophenyl, or 4-cyanophenyl). [Aspect 10] The method of any one of embodiments 1-7, comprising a compound of formula I, wherein Z is phenyl substituted with one fluoro (e.g., 2-fluorophenyl, 3-fluorophenyl, or 4-fluorophenyl). [Aspect 11] R with 1 or more Zs 4 The method of any one of aspects 1-7, comprising a compound of Formula I that is an optionally substituted heteroaryl moiety (eg, pyridyl, indazolyl, benzimidazolyl, benzisoxazolyl). [Aspect 12] The method of embodiment 11, comprising a compound of formula I, wherein heteroaryl is a monocyclic 5- or 6-membered heteroaryl (e.g., pyridyl, pyrimidyl, pyrazinyl, thiophenyl, pyrrolyl, thiophenyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl). [Aspect 13] The method of embodiment 11, comprising a compound of formula I, wherein heteroaryl is a bicyclic 9- or 10-membered heteroaryl (e.g., indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, benzodioxolyl, 2-oxo-tetrahydroquinolinyl). [Aspect 14] heteroaryl is one R selected from halo (e.g., fluoro, chloro, bromo, or iodo) and cyano; 4 The method of embodiment 11, comprising a compound of formula I that is substituted with a moiety (e.g., heteroaryl is 6-fluoro-3-indazolyl, 6-chloro-3-indazolyl, 6-fluoro-3-benzisoxazolyl, or 5-chloro-3-benzisoxazolyl). [Aspect 15] The compounds each independently are in free form or in pharma- ceutically acceptable salt form:
change
change
change
Claims
1. A pharmaceutical composition for the treatment of neuropathic pain, comprising a compound of formula I: 【Chemistry 1】 [In the formula, R 1 is H, C 1-6 Alkyl, —C(O)—O—C(R a )(R b )(R c ), -C(O)-O-CH 2 -O-C(R a )(R b )(R c ) or -C(R 6 )(R 7 )-O-C(O)-R 8 and R 2 and R 3 are independently H, D, C 1-6 Alkyl, C 1-6 selected from alkoxy, halo, cyano, or hydroxy; L is C 1-6 Alkylene, C 1-6 Alkoxy, C 2-3 Alkoxy C 1-3 Alkylene, C 1-6 Alkylamino or N-C 1-6 Alkyl C 1-6 Alkylamino, C 1-6 Alkylthio, or C 1-6 alkylsulfonyl, each of which is one or more R 4 may be substituted with a moiety; Z is selected from aryl and heteroaryl, where the aryl or heteroaryl is selected from one or more R 4 may be substituted with a moiety; Each R 4 is independently 1-6 Alkyl, C 1-6 selected from alkoxy, halo, cyano, or hydroxy; R 8 is -C(R a )(R b )(R c ), -O-C(R a )(R b )(R c ), or -N(R d )(R e ) and R a , R b and R c are each independently H and C 1-24 alkyl; R d and R e are each independently H and C 1-24 alkyl; R 6 and R 7 are each independently H, C 1-6 Alkyl, carboxy and C 1-6 alkoxycarbonyl] A pharmaceutical composition comprising a compound represented by the formula: The neuropathic pain is caused by mononeuropathy, plexopathy, radiculopathy, or polyneuropathy; Pharmaceutical compositions.
2. R 1 The pharmaceutical composition of claim 1 , wherein
3. R 1 C 1-6 The pharmaceutical composition of claim 1 , wherein the aryl group is alkyl.
4. The pharmaceutical composition of claim 1, wherein R 1 is methyl.
5. R 1 is -C(O)-O-C(R a )(R b )(R c ), -C(O)-O-CH 2 -O-C(R a )(R b )(R c ) or -C(R 6 )(R 7 )-O-C(O)-R 8 The pharmaceutical composition of claim 1 ,
6. L is unsubstituted C 1-6 alkylene or L is one or more R 4 C substituted with moiety 1-6 The pharmaceutical composition of claim 1 , wherein the alkylene is aryl.
7. L is unsubstituted C 1-6 Alkoxy or L is one or more R 4 C substituted with moiety 1-6 The pharmaceutical composition of claim 1 , wherein the aryl group is alkoxy.
8. R 1 , R 2 and R 3 The pharmaceutical composition of any one of claims 1 to 7, wherein each is H.
9. R 1 is H, and R 2 and R 3 The pharmaceutical composition according to any one of claims 1 to 7, wherein each of
10. Z is one or more R 4 The pharmaceutical composition according to any one of claims 1 to 7, wherein the moiety is an optionally substituted aryl.
11. Z is one R selected from halo and cyano. 4 The pharmaceutical composition of any one of claims 1 to 7, wherein the phenyl is substituted with a moiety.
12. The pharmaceutical composition according to any one of claims 1 to 7, wherein Z is phenyl substituted with one fluoro.
13. Z is one or more R 4 The pharmaceutical composition according to any one of claims 1 to 7, wherein the moiety is an optionally substituted heteroaryl.
14. 14. The pharmaceutical composition of claim 13, wherein the heteroaryl is a monocyclic 5- or 6-membered heteroaryl.
15. 14. The pharmaceutical composition of claim 13, wherein the heteroaryl is a bicyclic 9- or 10-membered heteroaryl.
16. Heteroaryl is one R selected from halo and cyano. 4 The pharmaceutical composition of claim 13 , wherein the compound is substituted with a moiety.
17. The pharmaceutical composition of claim 1, wherein R 1 is H, R 2 and R 3 are H, and L is unsubstituted ethylene, propylene, or butylene, propoxy, or butoxy.
18. The pharmaceutical composition of claim 17, wherein Z is phenyl substituted with one R 4 moiety selected from halo and cyano.
19. The pharmaceutical composition of claim 17, wherein Z is heteroaryl optionally substituted with one or more R 4 moieties, said heteroaryl being pyrrolidyl, pyrimidyl, pyrazinyl, thiophenyl, pyrrolyl, thiophenyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, or thiazolyl.
20. The pharmaceutical composition of claim 19, wherein said heteroaryl is substituted with one R 4 moiety selected from halo and cyano.
21. The pharmaceutical composition of claim 17, wherein Z is heteroaryl optionally substituted with one or more R4 moieties, and the heteroaryl is indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, benzodioxolyl, or 2-oxo-tetrahydroquinolinyl.
22. The pharmaceutical composition of claim 21, wherein said heteroaryl is substituted with one R 4 moiety selected from halo and cyano.
23. The compounds each independently are in free form or in pharma- ceutically acceptable salt form: 【Chemistry 2】 The pharmaceutical composition of claim 1, selected from the group consisting of:
24. The compounds each independently are in free form or in pharma- ceutically acceptable salt form: 【Chemistry 3】 The pharmaceutical composition of claim 1, selected from the group consisting of:
25. The compound, in free form or in the form of a pharma- ceutically acceptable salt, 【Chemistry 4】 The pharmaceutical composition of claim 1 ,
26. The pharmaceutical composition of any one of claims 1 to 25, wherein the compound of formula I is in the form of a pharma- ceutically acceptable salt.
27. 26. The pharmaceutical composition according to any one of claims 1 to 25, comprising a compound of formula I in admixture with a pharma- ceutically acceptable diluent or carrier, which may be in a sustained or delayed release formulation, and wherein the compound of formula I is optionally in a polymer matrix.
28. A pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by mononeuropathy.
29. The pharmaceutical composition described in claim 27, wherein the neuropathic pain is caused by a single mononeuropathy.
30. The pharmaceutical composition described in claim 29, wherein the mononeuropathy is focal mononeuropathy, compressive mononeuropathy, or entrapment mononeuropathy.
31. A pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by multiple mononeuropathy or polyneuritis.
32. The pharmaceutical composition described in claim 31, wherein the polyneuropathy is diabetic polyneuropathy.
33. A pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by drug-induced neurotoxicity.
34. The pharmaceutical composition described in claim 33, wherein the drug-induced neurotoxicity is caused by a platinum chemotherapeutic agent, a vinca alkaloid, or an antiretroviral nucleoside.
35. The pharmaceutical composition of claim 33, wherein the drug-induced neurotoxicity is caused by doxorubicin, etoposide, gemcitabine, ifosfamide, interferon alpha, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin, phenanthriplatin, picoplatin, satraplatin, vinblastine, vincristine, vindesine, vinorelbine, vinpocetine, didanosine, stavudine, or zalcitabine.
36. The pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by postherpetic neuralgia (PHN).
37. A pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by a plexus disorder.
38. A pharmaceutical composition described in any one of claims 1 to 25, wherein the neuropathic pain is caused by radiculopathy.
39. 26. The pharmaceutical composition of any one of claims 1 to 25, wherein the patient has previously been treated with another pain relieving drug, to which the patient did not respond adequately.
40. The pharmaceutical composition of claim 39, wherein the patient's pain was not adequately relieved or the patient suffered side effects that prevented continued treatment.
Citation Information
Patent Citations
organic compounds
JP2021519267A
organic compounds
JP2022515158A
Organic compounds
US20170319580A1
Organic compounds
WO2018126143A1
Organic compounds
WO2019023062A1
